Skip to main content
eLife logoLink to eLife
. 2017 Jan 3;6:e19273. doi: 10.7554/eLife.19273

Atomic structures of fibrillar segments of hIAPP suggest tightly mated β-sheets are important for cytotoxicity

Pascal Krotee 1,2,3,4,*, Jose A Rodriguez 1,2,4, Michael R Sawaya 1,2,4, Duilio Cascio 1,2,4, Francis E Reyes 5, Dan Shi 5, Johan Hattne 5, Brent L Nannenga 5, Marie E Oskarsson 6, Stephan Philipp 7, Sarah Griner 1,2,4, Lin Jiang 3,8,9, Charles G Glabe 7,10, Gunilla T Westermark 6, Tamir Gonen 5, David S Eisenberg 1,2,3,4,*
Editor: Nir Ben-Tal11
PMCID: PMC5207774  PMID: 28045370

Abstract

hIAPP fibrils are associated with Type-II Diabetes, but the link of hIAPP structure to islet cell death remains elusive. Here we observe that hIAPP fibrils are cytotoxic to cultured pancreatic β-cells, leading us to determine the structure and cytotoxicity of protein segments composing the amyloid spine of hIAPP. Using the cryoEM method MicroED, we discover that one segment, 19–29 S20G, forms pairs of β-sheets mated by a dry interface that share structural features with and are similarly cytotoxic to full-length hIAPP fibrils. In contrast, a second segment, 15–25 WT, forms non-toxic labile β-sheets. These segments possess different structures and cytotoxic effects, however, both can seed full-length hIAPP, and cause hIAPP to take on the cytotoxic and structural features of that segment. These results suggest that protein segment structures represent polymorphs of their parent protein and that segment 19–29 S20G may serve as a model for the toxic spine of hIAPP.

DOI: http://dx.doi.org/10.7554/eLife.19273.001

Research Organism: Human

eLife digest

In Type-II Diabetes, an individual’s cells fail to respond correctly to the hormone insulin, leaving them unable to counteract high levels of sugar in the blood. Another hormone, human islet amyloid polypeptide (hIAPP), works with insulin to regulate blood sugar levels. hIAPP is an amyloid protein, which means that it can lose its normal structure and form fibrils. Fibrils are difficult for cells to break down and are often associated with disease. Indeed, fibrils of hIAPP often form in the pancreas as part of Type-II Diabetes.

Some studies have shown that hIAPP fibrils are toxic to pancreatic cells and worsen the symptoms of Type-II Diabetes. Others suggest that it is the process of fibril formation that is toxic, not the fibrils themselves. Although the structures of the fibrils have been described, whether these structures cause cell toxicity has not been investigated.

Krotee et al. have now explored the structures of two overlapping segments of hIAPP using a new cryo electron microscopy method called MicroED that is ideal for studying such segments. One segment, called 19-29 S20G, forms a standard amyloid fibril structure that is similar to the structure of full-length hIAPP fibrils. Adding these segments to human cells causes similar levels of toxicity as the full-length hIAPP fibrils. The second segment, called 15-25 WT, forms a non-toxic structure that is less stable than standard amyloid fibrils.

The results presented by Krotee et al. support the view that standard amyloid fibril structures are toxic to cells and suggest that 19-29 S20G may be a good model to use when studying how full-length hIAPP fibrils behave. The structure of 19-29 S20G may also be useful as a template for designing molecules that block amyloid fibril growth. If amyloid fibrils cause cell toxicity in the pancreas, then these molecules could be used to treat Type-II Diabetes.

DOI: http://dx.doi.org/10.7554/eLife.19273.002

Introduction

Amyloid fibrils are associated with more than 25 diseases, including Alzheimer’s disease, Parkinson’s disease, and Type-II Diabetes (T2D) (Eisenberg and Jucker, 2012). The fibrils observed in each disease are composed of a particular protein; in T2D, amyloid fibrils are composed of human islet amyloid polypeptide (hIAPP) (Westermark et al., 1987; Cooper et al., 1988). hIAPP is a 37 residue polypeptide hormone that is co-secreted with insulin to modulate glucose levels (Roberts et al., 1989; Westermark et al., 2011).

Researchers have accumulated substantial evidence for a correlation between hIAPP aggregation and pancreatic β-cell death in the course of the disease, T2D. Approximately 90% of pancreatic tissue samples taken post-mortem from T2D patients contain islet amyloid primarily composed of hIAPP (Höppener et al., 2000). The extent of islet amyloid positively correlates with pancreatic β-cell loss and insulin dependence (Maloy et al., 1981; Esapa et al., 2005; Jurgens et al., 2011). Additional support for a link comes from comparison of human and mouse IAPP: mouse IAPP differs from human IAPP by only six residues, 3 of which are β-strand breaking prolines. Consequently, mouse IAPP does not aggregate (Nishi et al., 1989; Westermark et al., 1990). Moreover, mice can be induced to develop islet amyloid and T2D when they are engineered to express human IAPP and fed a high fat diet (Verchere et al., 1996; Westermark et al., 2000). Perhaps the strongest support for a link is the mutation in hIAPP, hIAPP-S20G; segments that contain this mutation aggregate more quickly, contribute to increased pancreatic β-cell apoptosis, and are associated with early onset T2D in families who carry this lesion (Sakagashira et al., 2000; Cao et al., 2012; Meier et al., 2016; Sakagashira et al., 1996; Lee et al., 2001; Morita et al., 2011).

Although a link between hIAPP aggregation and pancreatic β-cell death is well established, precisely which type of hIAPP aggregate contributes to pancreatic β-cell death and insulin dependence remains undetermined. Using mostly in vitro studies, researchers have presented evidence for toxicity of multiple types of hIAPP aggregates. Early studies suggest that amyloid fibrils are the primary cytotoxic species because preparations that contain fibrillar hIAPP were more cytotoxic than soluble preparations of the protein (Lorenzo et al., 1994; Lorenzo and Yankner, 1994; Schubert et al., 1995; Kapurniotu, 2001). Using cells and transgenic rodents as disease models, other studies found hIAPP fibrils to be associated with apoptosis, β-cell loss, and T2D severity (O'Brien et al., 1995; Hiddinga and Eberhardt, 1999; Janson et al., 1996; Hull et al., 2005a, 2005b; Pilkington et al., 2016). In contrast, some studies show that the process of hIAPP fibril formation, not the amyloid fibrils themselves, is the source of toxicity (Schlamadinger and Miranker, 2014; Oskarsson et al., 2015). However, most current research studies suggest soluble pre-fibrillar oligomers are the primary type of toxic aggregate. Support for oligomers as the primary cytotoxic species comes from the observation of oligomers associated with caspase activity and ER stress, which precede the formation of extracellular amyloid fibrils (Meier et al., 2006; Ritzel et al., 2007; Bram et al., 2014; Mukherjee et al., 2015; Lin et al., 2007; Huang et al., 2007; Haataja et al., 2008; Abedini et al., 2016). Several recent studies show that hIAPP fibrils are relatively inert and do not exert obvious toxicity. Despite these extensive in vitro studies, it is not clear that the toxic aggregates they describe also elicit toxicity in vivo.

In closer agreement with earlier studies, we find that hIAPP preparations that contain fibrils are cytotoxic to a rat pancreatic β-cell line, thus motivating us to determine the structure of the spine of hIAPP fibrils. If fibrils are a bona fide type of toxic aggregate in vivo, then determining the atomic structure of the spine of hIAPP fibrils is a logical approach for advancing our understanding of disease-relevant targets (Wiltzius et al., 2008, 2009a; Soriaga et al., 2016). Furthermore, we can utilize atomic structures as templates for structure-based design of novel therapeutics that may protect against pancreatic β-cell death. Although full-length amyloid proteins have so far been resistant to crystallization, select protein segments that form the spines of amyloid fibrils do form crystals(Nelson et al., 2005; Sawaya et al., 2007; Rodriguez et al., 2015). Indeed, the atomic structures of nearly 90 amyloid spines have been revealed in this manner. Other studies have taken an alternative approach: they employed solid-state NMR to gain detailed structural insights into hIAPP fibril structure (Luca et al., 2007; Weirich et al., 2016); some of these structures have spurred successful inhibitor designs (Mirecka et al., 2016). Here, we use the cryoEM method MicroED to determine the atomic structure of two 11-residue segments, termed spine segments, that span the amyloid spine of hIAPP.

Results

hIAPP preparations that contain fibrils are cytotoxic to cultured rat pancreatic β-cells

To compare the cytotoxic effects of oligomeric and fibrillar hIAPP, we generated hIAPP preparations that contained either amyloid oligomers or fibrils. We did this by aging the same concentration of hIAPP for 0 and 24 h time periods. Aging hIAPP for 24 h yielded amyloid fibrils and no detectable oligomers as assessed by Thioflavin-T (ThT) binding, negative-stain transmission electron microscopy (TEM), and a dot blot assay using the fibrillar oligomer-sensitive antibody, LOC (Figure 1A). Aging hIAPP for 0 h, which is a freshly dissolved hIAPP sample, yielded oligomers as assessed by a dot blot assay using LOC, and no amyloid fibrils (Figure 1—figure supplement 1A). Of note, we probed both hIAPP preparations with 25 different conformational antibodies that are known to bind soluble oligomers, but only LOC showed binding to any of our preparations. Although LOC was raised against hIAPP fibrils (Kayed et al., 2007), studies show that it also recognizes fibrillar oligomers (Wu et al., 2010), which share structural epitopes with amyloid fibrils and are structurally distinct from A11-positive pre-fibrillar oligomers.

Figure 1. Preparations of hIAPP that contain amyloid fibrils are cytotoxic to a rat pancreatic β-cell line.

(A) Human IAPP (hIAPP) aged for 24 h contains amyloid fibrils and no detectable oligomers. Amyloid fibrils were observed using ThT binding and TEM. Oligomers were detected using a dot bot assay with the polyclonal anti-oligomer antibody, LOC. hIAPP oligomers were used as the positive control for LOC binding. The dashed line on the ThT binding graph indicates ThT fluorescence of vehicle alone. (B) and (C) hIAPP aged for 24 h is significantly more cytotoxic than hIAPP aged for 0 h. In these experiments, 50 μM human and mouse IAPP were aged for the designated time periods and then they were applied to cells at 5 μM final concentration. Mouse IAPP (mIAPP), which does not form amyloid fibrils, is not cytotoxic regardless of time period of aging. Black horizontal bars indicate the median (n = 12–15 across 4–5 biological replicates, each with three technical replicates). (B) Rin5F cells treated with hIAPP aged for 24 h reduce significantly less MTT dye than Rin5F cells treated with hIAPP aged for 0 h (ns=not significant; ****p<0.0001 using an unpaired t-test with equal standard deviations). (C) Rin5F cells treated with hIAPP aged for 24 h exhibit significantly higher caspase-3/7 activation than Rin5F cells treated with hIAPP aged for 0 h. Additionally, Rin5F cells treated with hIAPP aged for 24 h exhibit significantly higher caspase-3/7 activation than vehicle-treated cells (***p=0.0008 using an ordinary one-way ANOVA), but Rin5F cells treated with hIAPP aged for 0 h do not (p=0.4286 using an ordinary one-way ANOVA) (ns=not significant; **p=0.0011 using an unpaired t-test with equal standard deviations). (D) The insoluble fraction of hIAPP aged 24 h, which contains amyloid fibrils and no detectable oligomers, contains the cytotoxic species. Cytotoxicity was measured using MTT dye reduction and detection of caspase-3/7 activation (****p<0.0001; **p<0.0013; n = 9 across three biological replicates, each with three technical replicates). (E) Amino acid sequences of human IAPP and mouse IAPP. The location of the early onset familial mutation, S20G, is shown below the human sequence. Red residues in the mouse sequence differ from the human sequence. The amyloid spine of human IAPP and the corresponding region in the mouse sequence is enclosed in the gray box. (F). Schematic of protein segments that span the amyloid spine, hereon referred to as spine segments, targeted for characterization. (G) Fibrils of spine segments seed hIAPP fibril formation, suggesting that spine segments embody structural characteristics of full-length hIAPP fibrils. 10 μM hIAPP was seeded with 10% (v/v) monomer equivalent of pre-formed, unsonicated seed of each spine segment. mIAPP, which does not contain amyloid fibrils, does not seed hIAPP fibril formation. Curves show average of 4 technical replicates.

DOI: http://dx.doi.org/10.7554/eLife.19273.003

Figure 1.

Figure 1—figure supplement 1. Characterization of hIAPP aged for 0 h and the soluble and insoluble fractions of hIAPP aged for 24 h.

Figure 1—figure supplement 1.

(A) hIAPP aged for 0 h contains oligomers and no detectable amyloid fibrils as assessed by ThT binding, TEM, and a dot blot assay using the anti-oligomer antibody, LOC. hIAPP oligomers were used as the positive control for LOC binding. (B) The insoluble fraction of hIAPP aged for 24 h, which contains the cytotoxic species, is composed of amyloid fibrils and no detectable oligomers. The soluble fraction, which is not cytotoxic, contains no detectable amyloid fibrils or oligomers. The dashed line on the ThT binding graphs indicates ThT fluorescence of vehicle alone.
Figure 1—figure supplement 2. All spine segments form amyloid fibrils or 3D crystals only a few hundred nanometers thick, as observed using TEM.

Figure 1—figure supplement 2.

Fibrils and 3D crystals were formed by dissolving lyophilized protein segments at 1 mM in PBS and 1% DMSO and incubating them for one week at room temperature under quiescent conditions. Fibril and crystal formation occurred as quickly as a few hours (19–29 S20G) to as long as overnight (15–25 WT and 15–25 S20G). (A) 15–25 WT forms striated ribbons. (B) 15–25 S20G forms striated ribbons. (C) 19–29 WT forms both striated ribbons and twisted fibrils of varying widths. (D) 19–29 S20G forms 3D crystals only a few hundred nanometers thick. Right panel scale bar is 1 μm.
Figure 1—figure supplement 3. Technical replicates and control samples for ThT assay in Figure 1G.

Figure 1—figure supplement 3.

(A) Fibrils of spine segments seed hIAPP fibril formation. All four technical replicates performed in the experiment in Figure 1G are shown. (B) Seeds of spine segments (1 μM) do not bind ThT. The graph shows mean ThT fluorescence across four technical replicates.

We observe that hIAPP preparations that contain fibrils are significantly more cytotoxic to rat pancreatic β-cells than hIAPP preparations that contain oligomers but no detectable fibrils (Figure 1B and C). We assayed the cytotoxicity of the hIAPP preparations to Rin5F cells, a rat pancreatic β-cell line (Gazdar et al., 1980) using two metrics: 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) dye reduction, an indicator of good metabolic health (Mosmann, 1983; Liu et al., 1997), and activation of caspase-3/7, an indicator of apoptosis (Budihardjo et al., 1999). Furthermore, the insoluble fraction of the hIAPP 24 h sample, which contains fibrils (Figure 1—figure supplement 1B), is cytotoxic, while the soluble fraction is not (Figure 1D), further suggesting that fibrils are the toxic aggregate in our studies.

Although we do not detect oligomers in the 24 h sample, we cannot rule out the possibility that it may contain some undetectable population of slowly forming, yet highly toxic oligomers that associate with fibrils. Despite this possibility, we chose to focus on studying fibrillar structures of hIAPP.

Selection of amyloid spine segments for structural studies

Given that hIAPP fibrils are cytotoxic, we sought to identify the residues that compose their amyloid spine. We identified residues 15–29 as the amyloid spine based on several lines of evidence and previous work by others (Westermark et al., 1990; Moriarty and Raleigh, 1999; Goldsbury et al., 2000; Tenidis et al., 2000). First, the sequence of mouse IAPP (mIAPP), which is non-amyloidogenic, differs from human IAPP only within this region (Figure 1E). Second, the only known familial disease mutation in hIAPP, hIAPP-S20G, also occurs within this region (Figure 1E) (Sakagashira et al., 2000; Cao et al., 2012). Third, previous work by our laboratory has shown that Phe15 may be part of the amyloid spine because it is required for stabilizing an on-pathway α-helical dimer and mutating this residue can delay fibril formation (Wiltzius et al., 2009b).

For these reasons, we chose to focus on two overlapping 11-residue segments within this region of the sequence: residues 19–29 and residues 15–25. We chose to study the WT and early onset S20G mutation segments (Figure 1F). All four spine segments form amyloid fibrils or crystals (Figure 1—figure supplement 2) that seed full-length hIAPP fibril formation (Figure 1G, Figure 1—figure supplement 3), suggesting that the spine segments embody structural characteristics of full-length hIAPP fibrils.

Segment 19–29 S20G forms pairs of β-sheets tightly mated by a dry interface

To determine the structure of segment 19–29 S20G, we used Micro-Electron Diffraction (MicroED). MicroED employs a standard cryo electron microscope (cryoEM) in diffraction mode for data collection from 3D crystals only a few hundred nanometers thick (Figure 2A; Figure 3A) (Shi et al., 2013; Nannenga et al., 2014a, 2014b; Hattne et al., 2015; Liu et al., 2016). Such thin crystals are capable of producing measurable Bragg peaks because electrons interact with matter more strongly than X-rays. Indeed, we found that the nano-sized 3D crystals used for MicroED produced higher resolution diffraction than relatively larger crystals suited for structure determination at a microfocus X-ray beamline (Figure 2A). Evidently, micron-thick needle crystals are sufficient for X-ray structure determination with six or seven residue peptides, but not for 11-residue peptides. These experiences closely mirrored those in the determination of the atomic structure of the toxic core of α-synuclein (Rodriguez et al., 2015), an 11-residue segment that forms the spine of amyloid fibrils associated with Parkinson’s disease.

Figure 2. Bragg peaks produced by MicroED from 3D crystals only a few hundred nanometers thick are observed at higher resolution than peaks produced by X-ray diffraction at a microfocus beamline from microcrystals 10,000 times larger.

Figure 2.

(A) 3D crystals of 19–29 S20G (right, inset) diffract to 1.6 Å using MicroED, a whole angstrom better resolution than the microcrystals of 19–29 S20G (left, inset). (B) 3D crystals of 15–25 WT (right, inset) diffract to 1.4 Å using MicroED, whereas microcrystals of 15–25 WT diffract to 2.2 Å using Microfocus X-rays (left, inset).

DOI: http://dx.doi.org/10.7554/eLife.19273.007

Figure 3. The MicroED atomic structure of segment 19–29 S20G reveals pairs of β-sheets mated by a dry interface.

(A) Electron micrograph of 3D crystals used for data collection. The red circle represents the area of the crystal used for diffraction. (B) Pairs of β-sheets are oriented face-to-face and they are tightly mated by a dry interface that excludes water. The dry interface is formed by tightly packed, interdigitating side-chains. This panel shows 5 β-strands or layers along the ‘a’ dimension of the unit cell; the average crystal used for data collection is 10,400 layers long in the ‘a’ dimension. (C) Orthogonal view of the steric-zipper formed by the dry interface. (D) The similarity between the fiber diffraction pattern calculated from the structure shown in Panel C and the fiber diffraction observed from full-length hIAPP fibrils supports the dry interface as a model for the amyloid spine of full-length hIAPP fibrils. Along the meridian (left panel), the dry interface and full-length hIAPP fibrils share reflections at 4.7 Å and and 2.4 Å (black arrows). Additionally, along the off-meridonal, the diffraction patterns share a reflection at 3.7 Å. It is difficult to see the reflection at 2.4 Å in the full-length hIAPP fiber diffraction image, but the reflection is clearly visible in the radial profile in Figure 3—figure supplement 1. Along the equator (right panel), the dry interface and full-length hIAPP fibrils share reflections at 10.0 Å and 5.0 Å (black arrows). The right panel is magnified 2X to more clearly show the low-resolution reflections along the equator.

DOI: http://dx.doi.org/10.7554/eLife.19273.008

Figure 3.

Figure 3—figure supplement 1. The crystal packing of segment 19–29 S20G reveals a second interface, termed the ‘Back-to-Back’ or wet interface, which does not form the amyloid spine.

Figure 3—figure supplement 1.

The wet interface does not form the amyloid spine because (1) the fiber diffraction pattern calculated from this interface does not match the fiber diffraction pattern collected from full-length hIAPP fibrils, (2) it contains waters, and (3) it possesses less side-chain interdigitation than the dry interface. (A) View of crystal packing down the ‘a’ dimension of the unit cell reveals the two different interfaces. The unit cell is outlined in red; waters are shown in cyan. (B) Orthogonal view of the wet interface. The wet interface buries only 153 Å2 of surface area per strand and it possesses a shape complementarity of 0.64.
Figure 3—figure supplement 2. Scatter plot of sheet RMSD from planarity values for all hIAPP protein segment structures determined to date.

Figure 3—figure supplement 2.

The values for the 19–29 S20G and 15–25 WT atomic structures are highlighted in green and purple, respectively.
Figure 3—figure supplement 3. 19-29 WT and S20G have similar fibrillar structures.

Figure 3—figure supplement 3.

(A) Side-by-side comparison of X-ray diffraction from 19–29 WT fibrils (left) and 19–29 S20G fibrils (right). (B). Overlaid radial profiles calculated from X-ray fiber diffraction in panel A. 19–29 WT (black) and S20G (gray) fibrils share strong reflections at 4.6 Å, 8.4–9 Å, and 34.7 Å.
Figure 3—figure supplement 4. Radial profile calculated from the X-ray diffraction pattern given by cytotoxic full-length hIAPP fibrils.

Figure 3—figure supplement 4.

Cytotoxic full-length hIAPP fibrils were prepared under the same conditions as in the cytotoxicity assays. Next, the fibrils were pelleted by centrifugation, washed with water to remove salt, and then applied between two glass capillary tubes as described by Sunde and co-workers (Sunde et al., 1997). The first peak on the left, which occurs at 37.3 Å, may represent a legitimate feature of full-length hIAPP fibrils, but it is too close to the beam stop to definitively makes this conclusion.

The MicroED atomic structure of segment 19–29 S20G reveals pairs of parallel in-register β-sheets mated face-to-face by interdigitation of side-chains and exclusion of water molecules (Figure 3B and C;Table 1). This arrangement is termed a class I steric-zipper. Such features are observed for amyloid spines of other proteins and have been associated with pathology (Nelson et al., 2005; Sawaya et al., 2007; Ivanova et al., 2009; Colletier et al., 2011; Liu et al., 2011). This zipper contains a tightly packed hydrophobic core consisting of Phe23, Ala25, and Ile27. Phe23 is the central and largest contributor the hydrophobic core, consistent with multiple other experiments (Tenidis et al., 2000; Griffiths et al., 1995; Jack et al., 2006; Madine et al., 2008). The dry interface buries 265 Å2 of surface area per strand, which equates to 24 Å2 per residue. This interface is one of the largest and most complementary of any structurally determined steric-zipper interface (Supplementary file 1); it has a shape complementary of 0.85. The dry interface is nearly as large as the toxic core of α-synuclein (Rodriguez et al., 2015), but with higher shape complementarity.

Table 1.

Statistics of MicroED data collection and atomic refinement.

DOI: http://dx.doi.org/10.7554/eLife.19273.013

Sample

19–29 S20G

15–25 WT

Excitation Voltage (kV)

200

200

Electron Source

field emission gun

field emission gun

Wavelength (Å)

0.0251

0.0251

Total dose per crystal (e/ Å2)

3.4

2.9

Frame rate (frame/s)

0.3–0.5

0.3–0.5

Rotation rate (°/s)

0.3

0.3

# crystals used

6

6

Total angular rotation collected (°)

68

68

Merging Statistics

19–29 S20G

15–25 WT

space group

P212121

P1

Unit cell dimensions

a, b, c (Å)

4.78, 18.6, 70.8

11.68, 18.18, 19.93

α, β, γ (°)

90, 90, 90

62.8, 88.9, 87.6

Resolution (Å)

1.9

1.4

Rmerge

10.6% (15.0%)

19.9% (50%)

# of reflections

1380 (221)

9014 (153)

Unique reflections

548 (115)

2180 (84)

Completeness

83% (65%)

75% (35.3%)

Multiplicity

2.5 (1.9)

4.1 (1.8)

I/σ

5.65 (3.65)

4.33 (1.10)

CC1/2 (Diederichs, 2013)

98.9%

98.5%

Refinement Statistics

19–29 S20G

15–25 WT

Reflections in working set

546

2177

Reflections in test set

53

218

Rwork

22.75%

22.47%

Rfree

27.49%

25.90%

RMSD bonds (Å)

0.01

0.008

RMSD angles (°)

1.2

1.2

Ramachandran (%)

Favored

100

100

Allowed

0

0

Outliers

0

0

PDB ID code

5KNZ

5KO0

EMDB ID code

EMD-8272

EMD-8273

*Highest resolution shell shown in parenthesis.

Rfactor=100x||Fobs||Fcalc||/|Fobs| .

Fcalc and Fobs are the calculated and observed structure factor amplitudes, respectively. Rwork refers to the Rfactor for the data utilized in the refinement and Rfree refers to the Rfactor for 10% of the reflections randomly chosen that were excluded from the refinement.

Percentage of residues in Ramachandran plot regions were determined using Molprobity (Chen et al., 2010).

The β-sheets of the 19–29 S20G atomic structure possess a curvature that is not common in shorter hIAPP protein segments (Wiltzius et al., 2008, 2009a; Soriaga et al., 2015). To assess β-sheet curvature, we compared the root mean square deviations (RMSD’s) of sheets from planarity across all hIAPP protein segment atomic structures determined to date (Supplementary file 1). The 19–29 S20G structure ranks in the upper half of the list (Figure 3—figure supplement 2), containing both sheet curvature and a sharp kink. Most of the shorter peptides are nearly flat, but some have sharp kinks. The significance of deviation from planarity is not yet clear.

The similarity between the fiber diffraction pattern calculated from this steric-zipper and the fiber diffraction pattern collected from full-length hIAPP fibrils tends to validate the 19–29 S20G atomic structure as a model for the amyloid spine of full-length hIAPP (Figure 3D). The diffraction patterns share several key features, including reflections at 4.7 Å and 2.4 Å along the meridian, a reflection at 3.7 Å along the off-meridian (left panel), and reflections at 10.0 Å and 5.0 Å along the equator (right panel).

Structural studies performed here and elsewhere by others suggest that 19–29 WT can form a similar dry interface to the one observed in the 19–29 S20G atomic structure. Radial profiles calculated from X-ray fiber diffraction of 19–29 WT and 19–29 S20G fibrils show strong reflections in common at 4.6 Å, 8.4 Å and 8.7 Å, and 34.7 Å, indicative of interstrand, intersheet, and proto-filament spacing, respectively (Figure 3—figure supplement 3). A previous study of 20–29 WT fiber diffraction revealed comparable reflections, which the authors used to formulate a fibril model of 20–29 WT that roughly agrees with our 19–29 S20G atomic structure (Madine et al., 2008). Our atomic structure and their model differ by a small shift in registration between sheets, allowing for tighter packing in the atomic structure. These results are consistent with earlier findings by Cao and co-workers, who observed that hIAPP-WT fibrils seed hIAPP-S20G fibril formation, thus suggesting a shared fibrillar structure (Cao et al., 2012).

Although the WT and mutant segments likely form similar structures, the structure of the mutant segment may be more stable. The stability of the mutant segment may stem from the early onset Gly20 mutation, which adopts an unusual geometry (φ = −101.7° and ψ = 107.5°) that creates a kink in the peptide backbone. To investigate this hypothesis, we generated a model of 19–29 WT consisting of a mated pair of ten-stranded sheets. The model was identical to the 19–29 S20G atomic structure with the exception that we adjusted the backbone torsion angles of Ser20 to comply with the allowed regions of the Ramachandran plot for a non-glycine residue. We compared the energies of the WT and S20G structures after minimization with FoldIt (Cooper et al., 2010). The dry interfaces are nearly identical between the two segments, except near Asn21, where the altered backbone torsion angles break the canonical Asn ladder hydrogen bonding interactions with neighboring Asn21 residues within the sheet and instead, form hydrogen bonds with Ser29 from the opposing sheet. The alteration separates the pair of sheets by approximately 1.5 Å in this region, and therefore the 19–29 S20G structure has a slightly lower energy than 19–29 WT (−590 REU vs. −535 REU).

Segment 15–25 WT forms an arrangement of labile unmated β-sheets

The atomic structure of segment 15–25 WT, also determined using MicroED (Figure 2B; Figure 4A), shows an arrangement of unmated β-sheets composed of anti-parallel out-of-register β-strands that is uncharacteristic of pathogenic amyloid fibrils (Figure 4B;Table 1). Most pathogenic amyloid fibrils are composed of β-strands that stack perpendicular to the sheet-long axis, but the β-strands in out-of-register structures stack at an angle. Deviation of strands from the fibril perpendicular is a natural consequence of the registration shift implied by out-of-register structures. The out-of-register β-strands are stabilized by extensive hydrogen bonding. Within each sheet, the β-strands form two distinct, unequal interfaces: a stronger interface with twelve hydrogen bonds, and a weaker interface with eight hydrogen bonds (Figure 4B). This inequality between interfaces has been observed in previous examples of out-of-register sheets (Soriaga et al., 2015; Laganowsky et al., 2012; Liu et al., 2012; Yu et al., 2015). A view down the ‘proto-fibril axis’ of the crystal shows that the faces of adjacent sheets are wet and overlap only partially (Figure 4C); the asymmetric unit contains density for seven ordered water molecules and one thiocyanate molecule. The area buried between adjacent sheets is small (10.7 Å2 per residue) compared to the average steric-zipper (20.1 Å2 per residue). Hence, there is no dry interface between adjacent sheets in the crystal, and the structure seems labile compared to that of 19–29 S20G.

Figure 4. Segment 15–25 WT forms an arrangement of unmated β-sheets that is uncharacteristic of pathogenic amyloid fibrils.

(A) Electron micrograph of 3D crystals used for data collection. The red circle represents the area of the crystal used for diffraction. (B) A single β-sheet contains anti-parallel out-of-register β-strands stabilized by two distinct, unequal interfaces: a stronger interface with twelve hydrogen bonds, and a weaker interface with eight hydrogen bonds. The β-strands are out-of-register by two residues because Leu16 on the first β-strand is directly above His18 on the third β-strand. (C) The view down the proto-fibril axis reveals hydrated interfaces between partially overlapping β-sheets. Notice that adjacent β-sheets lack side-chain interdigitation. Water molecules are shown as cyan spheres. The thiocyanate molecule is highlighted in gold in the central β-sheet and colored gray in the peripheral β-sheets.

DOI: http://dx.doi.org/10.7554/eLife.19273.014

Figure 4.

Figure 4—figure supplement 1. 15-25 WT fibrils are relatively weak and reversible compared to 19–29 S20G fibrils.

Figure 4—figure supplement 1.

Equimolar concentrations of 15–25 WT and 19–29 S20G fibrils were treated with increasing amounts of SDS and then heated at 55°C for 20 min. (A) Turbidity measurements of the fibrils treated with heat and increasing amounts of SDS reveal that 15–25 WT fibrils disaggregate more readily than 19–29 S20G fibrils. Turbidity measurements were obtained by recording absorbance at 340 nm. (B) Negative-stain electron micrographs corroborate the results observed in the turbidity measurements. Scale bars are 1 μm.
Figure 4—figure supplement 2. Scatter plot of sheet RMSD from planarity values for all hIAPP protein segment structures determined to date.

Figure 4—figure supplement 2.

The values for the 19–29 S20G and 15–25 WT atomic structures are highlighted in green and purple, respectively.
Figure 4—figure supplement 3. 15-25 WT and S20G have similar fibrillar structures.

Figure 4—figure supplement 3.

(A) Side-by-side comparison of X-ray diffraction from 15–25 WT fibrils (left) and 15–25 S20G fibrils (right). (B) Overlaid radial profiles calculated from X-ray fiber diffraction in panel A. 15–25 WT (black) and S20G (gray) fibrils display strong reflections at 4.7 Å, 9.3–9.8 Å, 18.2 Å, and 37.0 Å.

Consistent with our observation of unmated β-sheets in the atomic structure, we observe that 15–25 WT fibrils are relatively weak and reversible compared to 19–29 S20G fibrils, which possess a canonical pathogenic amyloid fibril architecture. Turbidity readings followed by negative-stain EM reveal that 15–25 WT fibrils completely disaggregate in the presence of heat and 1% SDS, but 19–29 S20G fibrils remain intact in up to 2% SDS (Figure 4—figure supplement 1).

Similar to 19–29 S20G, the 15–25 WT atomic structure reveals curved β-sheets. The sheets possess one of the highest RMSD’s of sheets from planarity for any hIAPP protein segment structure determined to date (Supplementary file 1, Figure 4—figure supplement 2).

X-ray fiber diffraction and radial profile analysis of 15–25 WT and 15–25 S20G fibrils indicate they form structures similar to each other (Figure 4—figure supplement 3). Taken together with the X-ray fiber diffraction data from the 19–29 segments, we conclude that the early onset S20G mutation does not confer a fibril morphology distinguishable from wild-type.

Structural polymorphs elicit different cytotoxic effects

Next we investigated the cytotoxic effects of the spine segments in order to determine if any of them were similarly cytotoxic to full-length hIAPP preparations. Although the cytotoxic mechanism of hIAPP is not fully understood, several reports show hIAPP induces mitochondrial dysfunction, alters cell metabolism, and initiates activation of pro-apoptotic machinery (Butler et al., 2003; Mulder and Ling, 2009; Zraika et al., 2010; Magzoub and Miranker, 2012; Tomasello et al., 2014). Based on these findings, we tested the cytotoxicity of the spine segments using MTT dye reduction (Mosmann, 1983; Liu and Schubert, 1997) and a FRET-based biosensor to assay altered metabolism and pro-apoptotic machinery activation (Paulsson et al., 2008), respectively.

Using MTT dye reduction, we observe that the labile 15–25 fibrils are not cytotoxic to HEK293 cells (Figure 5A), whereas 19–29 S20G fibrils have comparable cytotoxicity to full-length hIAPP fibrils (Figure 5B). To verify the cytotoxic effects of each sample, we examined the morphology of the treated cells under a light microscope. Additionally, in the context of residues 19–29, the S20G segment is significantly more cytotoxic than the WT segment, consistent with parent full-length hIAPP (Sakagashira et al., 2000; Meier et al., 2016) (Figure 5B). We did not detect any oligomers present in the 15–25 WT or 19–29 S20G fibril samples using the LOC antibody (Figure 5—figure supplement 1).

Figure 5. Segment 19–29 S20G forms the toxic core of hIAPP and segments 15–25 are not toxic.

(A and B) Fibrils were formed by incubating the spine segments overnight under quiescent conditions, the same conditions used to prepared full-length hIAPP fibrils. Next, the samples were applied to HEK293 cells at the specified concentrationsand then cell viability was quantified using MTT dye reduction. Bars show median cell viability; dashed lines show median cell viability from 10 μM mIAPP and hIAPP. (A) 15–25 WT and 15–25 S20G fibrils are not toxic compared to full-length hIAPP fibrils (n = 12 across four biological replicates, each with three technical replicates). (B) 19–29 WT fibrils are mildly cytotoxic and 19–29 S20G fibrils are significantly more cytotoxic than 19–29 WT fibrils (****p<0.0001 using a Mann-Whitney U test; n = 12 across four biological replicates, each with three technical replicates). 19–29 S20G fibrils (10 μM) are similarly cytotoxic to full-length hIAPP fibrils at the same concentration (lower dashed line) (p=0.09 using an unpaired t-test with equal standard deviations). (C) The insoluble fraction of the 50 μM 19–29 S20G cytotoxic preparation contains the cytotoxic species. 19–29 S20G fibrils were formed overnight at room temperature and then pelleted by centrifugation. The soluble fraction was carefully removed and then filtered to ensure it contained no insoluble material. The insoluble material was resuspended in its original volume. Each sample was applied to HEK293 cells and then cell viability was quantified with MTT dye reduction (***p<0.0002 using an ordinary one-way ANOVA; n = 3 technical replicates) (D) and (E) Using a FRET-based biosensor assay for monitoring caspase-3 activity in real-time, 19–29 S20G fibrils induce the most caspase-3 activity, whereas segments 15–25 did not induce caspase-3 activity, consistent with the MTT dye reduction assay results. 50 μM of each spine segment seeded with 166 nM seeds was applied to stably transfected CHO cells. (D) Fold difference was recorded over 24 h. Datapoints represent average fold difference. The dashed line represents the 16 h mark. (E) Average levels of caspase-3 activation after a 16 h incubation relative to untreated cells (***p<0.0002; ****p<0.0001 using an ordinary one-way ANOVA, Bonferroni correction; n = 5 technical replicates).

DOI: http://dx.doi.org/10.7554/eLife.19273.018

Figure 5.

Figure 5—figure supplement 1. Fibrillar samples of 15–25 WT and 19–29 S20G do not contain detectable amyloid oligomers.

Figure 5—figure supplement 1.

Oligomers were probed using a dot bot assay with the polyclonal anti-oligomer antibody, LOC. hIAPP oligomers were used as the positive control for LOC binding.
Figure 5—figure supplement 2. (−)-epigallocatechin gallate (EGCG), a flavanol known to mitigate full-length hIAPP cytotoxicity by preventing it from forming fibrils, likewise mitigates 19–29 S20G cytotoxicity by preventing it from forming fibrils.

Figure 5—figure supplement 2.

(A) Chemical structure of EGCG. (B) Negative-stain electron micrographs reveal that EGCG mitigates 19–29 S20G fibril formation. 19–29 S20G was incubated overnight at room temperature under quiescent conditions in buffer alone or with equimolar concentration of ECGC. Next, the samples were spotted onto carbon-coated copper grids for negative-stain EM analysis. (C) EGCG mitigates 19–29 S20G cytotoxicity. Samples were generated as described in panel B and then applied to HEK293 cells. Cell viability was quantified using MTT dye reduction. Columns indicate median cell viability. Different symbols correspond to values observed in each independent experiment (***p=0.0004 using a unpaired t-test with Welch’s correction for unequal variances; n = 9 across three biological replicates, each with three technical replicates). (D) Negative-stain EM reveals that EGCG does not mitigate fibril formation of 15–25 WT, a spine segment that does not possess a hydrophobic core. 15–25 WT was incubated for five days under shaking conditions with equimolar concentrations of EGCG. Next, the samples were spotted onto carbon-coated copper grids for negative-stain EM.

Based on our examination of the insoluble and soluble fractions of the cytotoxic 19–29 S20G sample, we determine that the cytotoxicity of 19–29 S20G mainly resides in its fibrillar form. We tested the cytotoxicity of the total, insoluble and soluble fractions of the 19–29 S20G sample to HEK293 cells using MTT dye reduction. We observe that the insoluble fraction, which contains amyloid fibrils, is similarly cytotoxic to the total (Figure 5C), just as we observed with full-length hIAPP (Figure 1D, Figure 1—figure supplement 1B). These results suggest that 19–29 S20G may form the toxic spine of full-length hIAPP.

Further evidence that 19–29 S20G may form the toxic spine of full-length hIAPP comes from our observation that (−)-epigallocatechin gallate (EGCG), a flavanol known to mitigate full-length hIAPP cytotoxicity by preventing hIAPP from forming fibrils (Meng et al., 2010), also mitigates 19–29 S20G cytotoxicity by preventing it from forming fibrils (Figure 5—figure supplement 2B and C). We hypothesize that EGCG may mitigate fibril formation of full-length hIAPP and 19–29 S20G by binding to a common site, such as the dry interface of the amyloid spine. A previous study suggested EGCG may mitigate hIAPP fibril formation by binding hIAPP via hydrophobic interactions (Young et al., 2015). Indeed, EGCG does not prevent fibril formation of 15–25 WT, which does not possess a dry hydrophobic interface (Figure 5—figure supplement 2D). In addition, these results further support our conclusion that preparations of segment 19–29 S20G that contain fibrils are cytotoxic.

Next we tested whether the spine segments activate pro-apoptotic machinery using a FRET-based biosensor assay for monitoring caspase-3 activity in real-time (Paulsson et al., 2008). In this assay, CHO cells are stably transfected with a construct containing enhanced cyan fluorescent protein (ECFP) and enhanced yellow fluorescent protein (EYFP) fused by a DEVD linker. FRET signal is observed by exciting ECFP at 440 nm. In cells undergoing apoptosis, active caspase-3-like proteases target and cleave the DEVD linker, resulting in loss of FRET signal. Cell viability is measured by monitoring the ratio of 540 nm/480 nm, which reports loss of FRET signal and increased caspase-3 activity.

Using this system, we observe that segment 19–29 S20G elicits the most caspase-dependent cytotoxicity of the spine segments and segments 15–25 are not cytotoxic (Figure 5D and E). Segment 19–29 S20G is not as cytotoxic as full-length hIAPP in this assay, possibly because hIAPP interaction with heparan sulfate proteoglycans (HSPG) is important for apoptosis induction (Oskarsson et al., 2015), and residues 1–8, which are missing in all of the spine segments, are required for hIAPP binding to HSPG’s.

Fibril seeds of 15–25 WT reduce the cytotoxicity of full-length hIAPP

Given that the spine segments seed full-length hIAPP fibril formation and that 19–29 S20G and 15–25 WT fibrils elicit different cytotoxic effects, we investigated whether seeding with either of the spine segments alters hIAPP cytotoxicity. To do this, we prepared seeded hIAPP at 10 μM with 10% monomer equivalent of pre-formed seeds, the same conditions used in the ThT assay in Figure 1G. For all cytotoxicity assays, we dilute samples 1 to 10 to the concentration specified in culture medium containing pre-plated cells. Thus, we tested the cytotoxicity of seeded hIAPP at 1 μM in order to preserve the conditions of the ThT assay.

Using MTT dye reduction, we observe that hIAPP seeded with non-toxic 15–25 WT fibrils is less cytotoxic than hIAPP alone, but hIAPP seeded with stable, toxic 19–29 S20G fibrils is similarly cytotoxic to hIAPP alone (Figure 6). Likewise, hIAPP seeded with stable, toxic 19–29 S20G fibrils is significantly more cytotoxic than hIAPP seeded with labile, non-toxic 15–25 WT fibrils (Figure 6). Seeds alone are not cytotoxic, indicating the cytotoxic effects we observe originate from the interaction of each seed with hIAPP and not the seed alone.

Figure 6. Fibril seeds of 15–25 WT reduce the cytotoxicity of full-length hIAPP.

In this experiment, we incubated 10 μM hIAPP with or without 10% monomer equivalent of pre-formed seeds overnight under quiescent conditions, the same conditions used to seed full-length hIAPP fibril formation in Figure 1. Next, we diluted the samples 1 to 10 in culture media containing pre-plated Rin5F cells. Note: the concentration of IAPP used in this experiment is less than the IAPP concentrations used in the cytotoxicity assays in Figures 1 and 5. hIAPP seeded with stable, toxic 19–29 S20G fibrils is more cytotoxic to Rin5F cells than hIAPP seeded with labile, non-toxic 15–25 WT fibrils. Columns indicate median cell viability (ns = not significant; **p=0.006; ****p<0.0001 using an unpaired t-test with equal standard deviations, n = 9 across three biological replicates, each with three technical replicates). 19–29 S20G seeds and 15–25 WT seeds (100 nM each) are not cytotoxic to Rin5F cells.

DOI: http://dx.doi.org/10.7554/eLife.19273.021

Figure 6.

Figure 6—figure supplement 1. hIAPP fibrils made by seeding with each spine segment have slightly different structural features.

Figure 6—figure supplement 1.

(A) Negative-stain electron micrographs reveal fibrils made by seeding with each spine segment do not have markedly different morphologies. Unseeded hIAPP forms pre-dominantly striated ribbons of uniform width that bundle together; some fibrils have twists (black arrow head). hIAPP fibrils made by seeding with stable, toxic 19–29 S20G fibrils form striated ribbons of varying widths and some twisted fibrils (black arrow head). hIAPP fibrils made by seeding with labile, non-toxic 15–25 WT fibrils form striated ribbons that appear slightly thinner than unseeded hIAPP fibrils. (B) and (C) X-ray fiber diffraction and radial profile analysis suggest hIAPP fibrils made by seeding with toxic and non-toxic segments have slightly different structures. hIAPP fibrils made by seeding with stable, toxic 19–29 S20G fibrils display shorter Bragg spacings compared to hIAPP fibrils made by seeding with labile, non-toxic 15–25 WT fibrils. The shorter spacings suggest tighter fibril packing.

There are two possible explanations for the reduced cytotoxicity of the seeded 15–25 WT sample. First, the 15–25 WT seeds may seed a non-toxic species of full-length hIAPP, or second, the 15–25 WT seeds may interact with full-length hIAPP in some way that reduces its cytotoxicity.

X-ray fiber diffraction and radial profile analysis of the hIAPP fibrils used in the cytotoxicity assay reveal that fibrils formed by seeding with stable, toxic 19–29 S20G fibrils have a slightly tighter packing than fibrils formed by seeding with labile, non-toxic fibrils. hIAPP fibrils formed by seeding with stable, toxic 19–29 S20G fibrils exhibit reflections indicative of shorter equatorial Bragg spacings than hIAPP seeded with labile, non-toxic 15–25 WT fibrils (9.0 Å versus 10.0 Å) (Figure 6—figure supplement 1). The tighter packing of these fibrils may explain their enhanced cytotoxicity. Fiber diffraction could not be detected from seeds alone prepared under the same conditions.

Discussion

In 1901, when Dr. Eugene Opie first observed islet amyloid in post-mortem pancreata of T2D patients, he proposed a link between the islet amyloid and T2D (Opie, 1901). Over a century later, multiple studies have shown an unequivocal link between hIAPP aggregation and T2D, but uncertainty remains about which type of hIAPP aggregate contributes to pancreatic β-cell death. Although most recent in vitro studies suggest soluble oligomers are the primary type of toxic aggregate, here, we find hIAPP samples that contain fibrils alter pancreatic β-cell metabolism and activate pro-apoptotic caspases.

These findings motivated us to determine the structure of the spine of hIAPP fibrils and elucidate structural features important for hIAPP cytotoxicity. To improve our likelihood of crystallization and structure determination, we selected four protein segments that span the spine. We discovered that segment 19–29 S20G forms a pair of β-sheets mated at a dry interface, a structure that shares key features with full-length hIAPP fibrils as described in the following paragraph. What’s more, the fibrillar form of 19–29 S20G is cytotoxic. In contrast, segment 15–25 WT forms an unusual arrangement of single, out-of-register β-sheets that are not cytotoxic. The divergence in structure and cytotoxicity of segments 19–29 S20G and 15–25 WT suggests that strong, stable intermolecular interactions are important features of cytotoxic amyloid proteins.

The experiments of this study show that the 19–29 S20G atomic structure recapitulates many of the structural features and cytotoxic properties of hIAPP. First, preparations of 19–29 S20G that contain fibrils are cytotoxic, as is the case for full-length hIAPP. Second, X-ray fiber diffraction calculated from the dry interface of the 19–29 S20G atomic structure shares key features with fiber diffraction collected from full-length hIAPP fibrils. Third, segment 19–29 S20G elicits cytotoxicity by altering cell metabolism and activating pro-apoptotic machinery, mechanisms by which full-length hIAPP fibrils are thought to contribute to pancreatic β-cell death during T2D. Fourth, the early onset S20G mutation confers greater cytotoxicity within segment 19–29 and within full-length hIAPP. Last, EGCG, a flavanol that mitigates full-length hIAPP fibril formation and cytotoxicity, likewise mitigates 19–29 S20G fibril formation and cytotoxicity. These results, taken together with the canonical pathogenic amyloid fibril architecture of segment 19–29 S20G, suggest it represents the toxic amyloid spine of hIAPP.

Our studies begin to provide a framework for understanding which hIAPP fibril polymorphs may contribute to pancreatic β-cell death during T2D. Previous structural studies of hIAPP protein segments (Wiltzius et al., 2008, 2009a; Soriaga et al., 2015) and full-length hIAPP (Luca et al., 2007; Weirich et al., 2016; Goldsbury et al., 1997; Kajava et al., 2005; Bedrood et al., 2012; Wineman-Fisher et al., 2015) identified an array of structures with diverse side-chain and sheet arrangements; the 15 hIAPP protein segment structures that overlap the hIAPP amyloid spine belong to six different steric-zipper classes (Figure 7). These multiple diverse structures suggest there is significant polymorphism within the hIAPP amyloid spine, but exactly which of these polymorphs elicit cytotoxicity was not known. By studying the structures and cytotoxic effects of protein segments in parallel, we identify a cytotoxic hIAPP fibril structure that may contribute to pancreatic β-cell death during T2D. Additionally, our studies suggest that not all hIAPP fibril structures are cytotoxic.

Figure 7. Schematic of structural features of all hIAPP protein segment structures determined to date.

Figure 7.

Parallel (//) or Anti-parallel (A//) refers to the orientation of β-strands within β-sheets. Registry refers to the translational offset of β-sheets perpendicular to the fiber axis.

DOI: http://dx.doi.org/10.7554/eLife.19273.023

Both atomic structures presented here reveal a new and potentially important observation: curved β-sheets. In the dry interface of the 19–29 S20G atomic structure, the curved β-sheets accommodate the tightly packed hydrophobic core, which includes a bulky phenylalanine, while maintaining high shape complementarity and large buried surface area. Paradoxically, in the 15–25 WT atomic structure, the curved β-sheets appear to have an opposite effect: the curved β-sheets appear to prevent adjacent sheets from associating to form a canonical pathogenic amyloid fibril architecture. In both atomic structures, the effect of the curved β-sheets is dictated by the registry of adjacent β-sheets (Supplementary file 1, Figure 7).

The 15–25 WT atomic structure joins the recently discovered class of out-of-register protein segment structures, which exert disparate cytotoxic effects. Here, we show that 15–25 WT is not cytotoxic but in contrast, the out-of-register protein segment KDWSFY from β2-microglobulin elicits mild cytotoxicity (Liu et al., 2012). One notable difference between the two structures is that the 15–25 WT structure is formed of single sheets, while the KDWSFY structure is formed of sheets mated by a dry interface. The dry interface of the KDWSFY atomic structure results in a higher solvation energy per strand compared to the 15–25 WT atomic structure (122 cal/mol/strand vs. 19 cal/mol/strand). Given that cytotoxic structures like 19–29 S20G have relatively high solvation energies per strand (279 cal/mol/strand; Supplementary file 1), this difference may explain the disparate cytotoxic effects of the two out-of-register structures. However, we need more studies of out-of-register protein structures and their cognate cytotoxic effects to definitively make this conclusion. The disparate cytotoxic effects within this structure class lead us to believe that the nature of cytotoxicity is not simply conferred by in-register or out-of-register structures. As many studies have suggested, there may be more than one mechanism of amyloid-related toxicity and the different mechanisms may be catalyzed by different architectures. Alternatively, maybe if additional residues were included, the anti-parallel out-of-register fiber could be stabilized, thereby increasing its toxicity.

Although the 19–29 WT fibrils prepared in this study appear morphologically similar to 19–29 S20G fibrils, the 19–29 WT fibrils are likely polymorphic and may contain some fraction of fibrils that are structurally similar to non-toxic 15–25 WT fibrils. Previous structural studies of segment 20–29 WT fibrils show that it forms an array of polymorphs, some of which are similar to the 15–25 WT atomic structure (Griffiths et al., 1995; Jack et al., 2006; Madine et al., 2008; Ashburn et al., 1992; Nielsen et al., 2009). Structural polymorphism of 19–29 WT fibrils may explain their lower cytotoxicity than 19–29 S20G fibrils, which are homogenous in structure.

These findings, expedited by MicroED, may inform our understanding of hIAPP fibril structures that contribute to pancreatic β-cell death in Type-II Diabetes patients. Going forward, we can use our toxic amyloid spine model as a template for structure-based design in the effort to develop much needed therapeutics that protect against pancreatic β-cell death and disease progression (Sievers et al., 2011; Kahn et al., 2014). In addition, if hIAPP fibrils truly are a major type of toxic aggregate that contributes to T2D, then raising antibodies against hIAPP fibrils may represent a promising strategy for therapeutic development, especially in light of the recent success of preliminary studies with antibodies raised against amyloid-β (Sevigny et al., 2016).

Materials and methods

IAPP and protein segments

Human IAPP(1–37)-NH2 wild-type and mouse IAPP(1–37)NH2 wild-type were synthesized by Innopep (San Diego, CA) and CS Bio (Menlo Park, CA) and purified to greater than 98% purity. Human and mouse IAPP were prepared by dissolving the lyophilized proteins at 0.25–1 mM in 100% HFIP and leaving them to dissolve for several hours to ensure complete solubility. Next, the HFIP was removed with a CentriVap Concentrator (Labconco, Kansas City, MO). After removal of the HFIP, the peptides were dissolved at 1 mM, 5 mM, or 10 mM in 100% DMSO. The DMSO peptide stocks were diluted 100-fold in filter-sterilized Dulbecco’s PBS (Cat. # 14200–075, Life Technologies, Carlsbad, CA). Samples were incubated at room temperature for the designated time periods.

All four spine segments were synthesized by GenScript (Piscataway, NJ) and purified to greater than 98% purity. Fibrils were formed by dissolving lyophilized peptide at 1 mM in PBS and 1% DMSO.

Crystallization

15-FLVHSSNNFGA-25 (15–25 WT). 15–25 WT was dissolved at 20 mg/ml in ice-cold, nano-pure water and then spin-filtered. Crystals were grown using the hanging drop vapor diffusion method at 4°C in 0.35 M NaSCN and 35% MPD. Crystals grew within several hours and reached maximum size in a week. 3D crystals only a few hundred nanometers thick grew alongside microcrystals in the same drops.

19-SGNNFGAILSS-29 (19–29 S20G). Microcrystals were grown using the hanging drop vapor diffusion method at 30°C in 0.2M acetate salts and 40% MPD. 3D crystals only a few hundred nanometers thick were grown in batch by dissolving lyophilized peptide at 1 mM in PBS and 1% DMSO without seeding. Crystals grew on the bench top at room temperature in several hours.

MicroED data collection

The procedures for MicroED data collection and processing largely follow published procedures (Hattne et al., 2015; Shi et al., 2016). Briefly, a 2–3 μL drop of crystals in suspension was deposited onto a Quantifoil holey-carbon EM grid then blotted and vitrified by plunging into liquid ethane using a Vitrobot Mark IV (FEI, Hillsboro, OR). Blotting times and forces were optimized to keep a desired concentration of crystals on the grid and to avoid damaging the crystals. Frozen grids were then either immediately transferred to liquid nitrogen for storage or placed into a Gatan 626 cryo-holder for imaging. Images and diffraction patterns were collected from crystals using an FEG-equipped FEI Tecnai F20 TEM operating at 200 kV and fitted with a bottom mount TVIPS TemCam-F416 CMOS-based camera. Diffraction patterns were recorded by operating the detector in a movie mode termed ‘rolling shutter’ with 2×2 pixel binning (Nannenga et al., 2014b). Exposure times for these images were either 2 or 3 s per frame. During each exposure, crystals were continuously unidirectionally rotated within the electron beam at a fixed rate of 0.3 degrees per second, corresponding to a fixed angular wedge of 0.6 or 0.9 degrees per frame.

Crystals that appeared visually undistorted and that were 100–300 nm thick produced the best diffraction. Datasets from individual crystals were merged to improve completeness and redundancy. Each crystal dataset spanned a wedge of reciprocal space ranging from 40–80°. We used a selected area aperture of approximately 1 μm. The geometry detailed above equates to an electron dose rate of less than 0.01 e2 per second being deposited onto our crystals.

Measured diffraction images were converted from TVIPS format into SMV crystallographic format, using in-house software (available for download at http://cryoem.janelia.org/downloads) (Hattne et al., 2015).

We used XDS to index and integrate the diffraction images and XSCALE (Kabsch, 2010) for merging and scaling together datasets originating from different crystals.

For 19–29 S20G, data from six crystals were merged to assemble the dataset used for molecular replacement. Of note, the resolution was cut off at 1.9 Å to facilitate subsequent rounds of structure refinement.

For, 15–25 WT, data from six crystals were merged to assemble the dataset used for molecular replacement. Of note, the diffraction pattern from the 15-25 WT crystals diffracted with MicroED reveal a pseudo two-fold symmetry. In line with this observation, we indexed and integrated the diffraction images with space group C2, but the datasets had relatively poor statistics compared to the P1 datasets and our attempts at refining molecular replacement solutions from the C2 datasets failed.

Structure determination

19–29 S20G. We determined the structure using molecular replacement. An idealized 7-residue poly-alanine strand led us to our atomic model. The solution was identified using Phaser (McCoy, 2007). A dataset merged from six crystals was used to identify the initial model, but subsequent rounds of model building and refinement were carried out using a dataset from a single crystal. Free R flags were copied over from the dataset merged from six crystals to the single crystal dataset. Subsequent rounds of model building and refinement were carried out using COOT and Phenix, respectively (Emsley and Cowtan, 2004; McCoy et al., 2005). Electron scattering factors were used for refinement.

15–25 WT. We determined the structure using molecular replacement. Dozens of search models were used, but an out-of-register β-strand model led us to our solution. The solution was identified using Phaser (McCoy, 2007). Subsequent rounds of model building and refinement were carried out using COOT and Phenix, respectively (Emsley and Cowtan, 2004; McCoy et al., 2005). Electron scattering factors were used for refinement. To aid in model building, we used a feature enhanced map (FEM), which sharpens B factors at high resolution (Afonine et al., 2015).

Calculations of the area buried and shape complementarity (SC) were performed with AREAIMOL (Lee and Richards, 1971; Collaborative Computational Project, Number 4, 1994) and SC (Connolly, 1983; Richards, 1977; Lawrence and Colman, 1993), respectively.

ThT binding

30 μL of human and mouse IAPP preparations used in the cytotoxicity assays in Figure 1 were pipetted into a black-wall 384-well plate and then mixed with 3 μL of 1 mM Thioflavin-T (ThT). Fluorescence was recorded with an excitation wavelength of 444 nm and an emission wavelength of 482 nm.

Dot blot assay

1 μL of each sample generated for cytotoxicity assays in Figure 1 and Figure 5A and B was applied to a nitrocellulose membrane (Cat. # 162–0146, BioRad, Hercules, CA). Next, the membrane was blocked in 5% (w/v) nonfat dry milk in PBS-T (T = 0.1% (v/v) Tween-20 (Cat. #BP337-500, Fisher)) for 1 hr at room temperature. After blocking, the membrane was incubated with a 1:100 dilution of LOC polyclonal rabbit serum (Pacific Immunology, Ramona, CA) in 5% (w/v) milk in PBS-T at 4°C overnight. The membrane was washed in PBS-T for 10 min three times, and then incubated with anti-rabbit secondary antibody (RRID:AB_2307391; Cat. #111-035-144, Jackson ImmunoResearch, West Grove, PA) diluted 1:10,000 in PBS-T for 1 hr at RT. The membrane was washed three more times, and then the signal was developed with Clarity Western ECL Substrate (Cat. #170–5061, BioRad) and documented with a CCD camera. Exposures ranging from 5 s to 5 min were collected, but the 5 min exposure was used in all figures.

Imaging and negative stain transmission electron microscopy

Samples were spotted onto grids (holey or non-holey) and allowed to settle on the grid for 160 to 180 s. Remaining liquid was wicked off and grids were left to dry before analyzing. Sample grids were analyzed on the TF20 Electron Microscope (FEI, Hillsboro, OR). Images were collected at 3500 or 6000x magnification with an additional 1.4x post-column magnification and recorded using a TIETZ F415MP 16 megapixel CCD camera.

Samples for negative-stain EM were spotted on non-holey carbon-coated grids andallowed to settle on the grid for 160 to 180 s. Remaining liquid was wicked off and then 2% uranyl acetate was applied to the grid. After 1 min, the uranyl acetate was wicked off. The grids were left to dry before analyzing on the T12 Electron Microscope (FEI). Images were collected at 3,200 or 15,000x magnification and recorded using a Gatan 2kX2k CCD camera.

Cell culture

Rin5F cells were purchased from ATCC (RRID:CVCL_2177; Cat. # CRL-2058, Manassas, VA). Cells were cultured in RPMI media (ATCC, Cat. # 30–2001) plus 10% heat-inactivated fetal bovine serum. Cells were cultured at 37°C in a 5% CO2 incubator. They tested negative for mycoplasma using a MycoAlert PLUS Detection Kit (Cat. #: LT07-701, Lonza, Switzerland) and they were authenticated using Cytochrome C Oxidase 1 (COX1) gene analysis by Laragen (Culver City, CA).

HEK293 c18 cells (hereon referred to as HEK293) were a gift from Carol Eng in the laboratory of Arnold J. Berk at UCLA, but they were originally purchased from ATCC (RRID:CVCL_6974). Cells were cultured in DMEM media (Cat. # 11965–092, Life Technologies) plus 10% heat-inactivated fetal bovine serum and 1% pen-strep (Life Technologies). Cells were cultured at 37°C in a 5% CO2 incubator. They tested negative for mycoplasma using a MycoAlert PLUS Detection Kit and they were authenticated using STR profiling (Laragen).

CHO cells were purchased from ATCC (RRID:CVCL_0214; Cat. #: CCL-61). Cells were cultured in RPMI 1640 with 11 mM glucose (Sigma) with 10% FBS, and 1% pen-strep. Cells were cultured at 37°C in a 5% CO2 incubator. They tested negative for mycoplasma using a PCR-based method and they were authenticated using mRNA analysis.

Spine segment fibril formation

Spine segments were dissolved at 1 mM in PBS with 1% DMSO. Samples were incubated at room temperature for 15 hr or up to one week under quiescent conditions to form fibrils. The presence of fibrils was confirmed with electron microscopy. Fibril samples were diluted appropriately for cell viability assays and fibril formation assays.

Fiber diffraction and radial profile analysis

Fibrils were spun down and washed with water three times to remove any salt. Fibrils of spine segments were spun down using a tabletop microfuge. Full-length hIAPP fibrils and spine segment seeds were spun down using an Airfuge Ultracentrifuge set at 75,000 rpm for 1 hr (Beckman-Coulter, Brea, CA). The samples were concentrated 10x in water and applied between two capillary ends and then the samples were left to dry overnight. Dried fibrils of spine segments and full-length hIAPP in Figure 3D were analyzed with a RIGAKU R-AXIS HTC imaging plate detector using Cu K(alpha) radiation from a FRE+ rotating anode generator with VARIMAX HR confocal optics (Rigaku, Tokyo, Japan). Fiber diffraction from full-length hIAPP fibrils used in Figure 6 was recorded by an ADSC Q315 CCD detector at the Advanced Photon Source 24-ID-E beamline (Argonne, IL).

Radial profiles were calculated using a program written in-house. The program calculates the average intensity as a function of distance from the beam center.

Thioflavin-T assays

Thioflavin-T (ThT) assays were performed in black 96-well plates (Nunc, Rochester, NY) sealed with UV optical tape. hIAPP and mIAPP were dissolved at 1 mM in 100% HFIP. The peptides were then diluted 100-fold in 20 mM sodium acetate pH 6.5 and 10 μM ThT. Unsonicated fibril seeds were added at 1 μM monomer equivalent concentration (10% v/v). ThT fluorescence was recorded with excitation and emission of 444 nm and 482 nm, respectively, using a SpectraMax M5 (Molecular Devices, Sunnyvale, CA). Experiments were performed in quadruplicate and readings were recorded every 3 min.

Model building and energy analysis of 19–29 WT and 19–29 S20G

To investigate whether 19–29 WT could form a similar structure to 19–29 S20G, we modeled a serine at position 20 in the 19–29 S20G atomic structure. We adjusted the backbone torsion angles so that they fell within the ‘allowed’ regions of the Ramachandran plot for a non-glycine residue (Emsley and Cowtan, 2004). We performed energy minimization using FoldIt (RRID:SCR_003788) (Cooper et al., 2010) and compared the energies of the resulting models of 19–29 WT and 19–29 S20G.

Cytotoxicity assays

HEK293 cells and Rin5F cells were plated at 10,000 and 27,000 cells per well in 90 μL, respectively, in 96-well plates (Cat. # 3596, Costar, Tewksbury, MA). Cells were allowed to adhere to the plate for 20–24 hr.

For the assay in Figures 1 and 50 μM full-length IAPP was aged in vitro for the designated incubation times. To generate the soluble and insoluble fractions, the ‘hIAPP 24 h’ preparation was centrifuged at 21,000xg for 45 min and then the supernatant, which is the soluble fraction, was carefully removed and transferred to a 0.1 μm spin filter tube. Next, the supernatant was filtered and the pelleted material, which is the insoluble fraction, was resuspended in the original total volume.

For the assays in Figure 5 and Figure 5—figure supplement 2, 1 mM spine segment and 100 μM full-length IAPP samples were generated by preparing the samples as described previously and then incubating them for 15 hr at room temperature under quiescent conditions. After the incubation period, the spine segments were diluted appropriately.

For all assays, 10 μL of sample was added to cells. By doing this, samples were diluted 1/10 from in vitro stocks. Experiments were done in triplicate.

The appropriate statistical test for significance was determined by assessing whether (1) The sample sets had a Gaussian distribution using a D’Agostino-Pearson omnibus normality test and (2) The sample sets had equal variance using a Bartlett’s test or F test. For samples with Gaussian distributions and equal variances, we employed an unpaired t-test with equal standard deviations. For samples with Gaussian distributions, but unequal variances, we employed an unpaired t-test with Welch’s correction. For samples with non-Gaussian distributions and unequal variances, we employed a Mann-Whitney U-test.

3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) dye reduction assay for cell viability

After a 24 hr incubation of samples with cells, 20 μL of Thiazolyl Blue Tetrazolium Bromide MTT dye (Sigma, St. Louis, MO) was added to each well and incubated for 3.5 h at 37°C under sterile conditions. The MTT dye stock is 5 mg/mL in Dulbecco’s PBS. Next, the plate was removed from the incubator and 100 μL of MTT stop solution (Cat. #4101, Promega, Madison, WI) was added to each well. We ensured the MTT crystals were fully dissolved by placing the plates on an orbital shaker (slow speed) for about an hour prior to taking measurements. Alternatively, the MTT assay was stopped by carefully aspirating off the culture media and adding 100 μL of 100% DMSO to each well. Absorbance was measured at 570 nm using a SpectraMax M5. A background reading was recorded at 700 nm and subsequently subtracted from the 570 nm value.

Cells treated with vehicle alone (PBS + 0.1% DMSO) were designated at 100% viable, and cell viability of all other treatments was calculated accordingly.

For the MTT reduction assay in Figure 6, a single data point from the mIAPP sample set was deemed an outlier based on 2 lines of evidence: (1) The data point was identified as an outlier using a Grubb’s test (α = 0.1) for outliers using the n = 9 sample set, and (2) When the sample set was pooled with more data collected for different experiments (n = 42), the data point was identified as an outlier using a more stringent Grubb’s test (α = 0.01).

Caspase-3/7 activation assay

We used the caspase-3/7 GLO assay (Cat. # G8091, Promega, Madison, WI) to detect caspase-3/7 activation. For this assay, Rin5F cells were plated as previously described in white-walled 96-well plates (Cat. # 3917, Costar, Tewksbury, MA). After the designated aging period of each hIAPP preparation, 10 μL of sample was added to cells and thus diluted 1/10 from in vitro stocks. Experiments were performed in triplicate. Samples were incubated with cells for 24 h. Next, cell culture media, caspase-3/7 reagent, and the cells were brought to room temperature. All media was aspirated from wells and then replaced with 25 μL of media and 25 μL of caspase-3/7 reagent and mixed thoroughly. The plate was incubated at room temperature for 30 min and then luminescence was measured using a SpectraMax M5. Experimental points were normalized to vehicle-treated cells, which were designated as 100%. Cells treated with 2 μM staurosporine were used as a positive control to ensure the assay kit worked correctly.

FRET-based real-time monitoring of caspase-3 activity

CHO cells were stably transfected with a vector producing EYFP and ECFP connected via a short linker containing the Asp-Glu-Val-Asp (DEVD) sequence targeted by activated caspase-3. The short linker allows fluorescence energy transfer (FRET) to occur between the two fluorophores. During apoptosis activated caspase-3 cleaves the linker resulting in a loss of FRET measured as a reduced 540 nm/480 nm emission ratio.

Cells were plated at 25,000 cells per well in black 96-well optical bottom plates (Nunc, Grand Island, NY) and the assay was performed in Krebs-Ringer (120 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 0.5 mM KH2PO4, pH 7.4) supplemented with 20 mM HEPES and 2 mM glucose (KRHG).

hIAPP peptides (1–37, 15–25 WT and S20G, 19–29 WT and S20G) (final peptide concentration 50 μM in 1% DMSO) were mixed with sonicated, preformed fibrils (seeds) made of the same peptide (corresponding to 166 nM of monomers) and immediately added to the plated cells. FRET was monitored in real-time by measuring emission at 480 nm and 540 nm with 440 nm excitation in a FLUOstar Omega microplate reader (BMG Labtech) over 24 hr at 37°C.

SDS sensitivity assay

Fibrils of 15–25 WT and 19–29 S20G at monomer equivalent concentrations were allowed to form for one week to ensure complete fibril formation. The samples were homogenized with vortexing, and then aliquoted to 0.5 mL tubes with equal volumes. Each fibril sample was treated with water or increasing amounts of SDS, and then heated at 55°C for 20 min. Next, an aliquot of each sample was transferred to a 384-well plate and turbidity was measured by recording absorbance at 340 nm. Each fibril sample was spotted onto a grid for negative-stain EM to analyze fibril abundance. The experiment was repeated twice, but the results of 1 experiment are shown in Figure 4—figure supplement 1.

Acknowledgements

We thank Dan Anderson for suggesting the use of FEM maps. We thank the Advanced Photon Source (APS) staff for beamline support during collection of fiber diffraction: M. Capel, K. Rajashankar, N. Sukumar, J. Schuermann, I. Kourinov and F. Murphy at NECAT beam lines 24-ID; the UCLA-DOE X-ray Crystallography Core Technology Center, Michael Collazo, and the UCLA-DOE Macromolecular Crystallization Core Technology Center for setting up initial crystallization screens; Ivo Atanasov and the Electron Imaging Center for NanoMachines (EICN) of California NanoSystems Institute (CNSI) at UCLA for the use of their electron microscopes; and the UCLA Statistical Consulting group for guidance on statistical computing. The UCLA-DOE X-ray and Macromolecular and Macromolecular Crystallization Core Technology Centers are supported in part by the Department of Energy grant DE-FC0302ER63421. Use of the Advanced Photon Source is supported by National Institutes of Health grants P41 RR015301 and P41 GM103403 and Department of Energy under Contract DE-AC02-06CH11357. We thank the Cure Alzheimer’s Fund, the Swedish Research Council (VR 2015–02297), the Swedish Diabetes Foundation, the Janelia Research Campus visitor program, HHMI, and the National Institutes of Health (NIH) (R01 AG029430) for support.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Funding Information

This paper was supported by the following grants:

  • National Institutes of Health R01 AG029430 to Pascal Krotee, Jose A Rodriguez, Michael R Sawaya, Duilio Cascio, Sarah Griner, David S Eisenberg.

  • Howard Hughes Medical Institute to Pascal Krotee, Jose A Rodriguez, Michael R Sawaya, Duilio Cascio, Francis E Reyes, Dan Shi, Johan Hattne, Brent L Nannenga, Sarah Griner, Tamir Gonen, David S Eisenberg.

  • Vetenskapsrådet VR 2015-02297 to Marie E Oskarsson, Gunilla T Westermark.

  • Swedish Diabetes Foundation to Marie E Oskarsson, Gunilla T Westermark.

  • Cure Alzheimer's Fund to Stephan Philipp, Charles G Glabe.

Additional information

Competing interests

The authors declare that no competing interests exist.

Author contributions

PK, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents.

JAR, Acquisition of data, Analysis and interpretation of data, Contributed unpublished essential data or reagents.

MRS, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents.

DC, Acquisition of data, Analysis and interpretation of data.

FER, Acquired MicroED diffraction data, Acquisition of data.

DS, Acquired MicroED diffraction data, Acquisition of data.

JH, Acquired MicroED diffraction data, Acquisition of data.

BLN, Acquired MicroED diffraction data, Acquisition of data.

MEO, Acquisition of data, Analysis and interpretation of data.

SP, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents.

SG, Performed preliminary, unpublished dot blot assays for initial cytotoxicity studies.

LJ, Conception and design, Analysis and interpretation of data.

CGG, Acquisition of data, Analysis and interpretation of data, Contributed unpublished essential data or reagents.

GTW, Suggested the FRET-based bionsensor assay; Analyzed and interpreted FRET-based biosensor assay results; Helped compose responses to reviewers' comments, Analysis and interpretation of data.

TG, Acquisition of data, Analysis and interpretation of data.

DSE, Conception and design, Analysis and interpretation of data, Drafting or revising the article.

Additional files

Supplementary file 1. Summary of structural features and biophysical properties of all hIAPP protein segment structures determined to date.

DOI: http://dx.doi.org/10.7554/eLife.19273.024

elife-19273-supp1.xls (41.5KB, xls)
DOI: 10.7554/eLife.19273.024

References

  1. Abedini A, Plesner A, Cao P, Ridgway Z, Zhang J, Tu LH, Middleton CT, Chao B, Sartori DJ, Meng F, Wang H, Wong AG, Zanni MT, Verchere CB, Raleigh DP, Schmidt AM, L-h T. Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics. eLife. 2016;5:e12977. doi: 10.7554/eLife.12977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Afonine PV, Moriarty NW, Mustyakimov M, Sobolev OV, Terwilliger TC, Turk D, Urzhumtsev A, Adams PD. FEM: feature-enhanced map. Acta Crystallographica Section D Biological Crystallography. 2015;71:646–666. doi: 10.1107/S1399004714028132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ashburn TT, Auger M, Lansbury PT. The structural basis of pancreatic amyloid formation: isotope-edited spectroscopy in the solid state. Journal of the American Chemical Society. 1992;114:790–791. doi: 10.1021/ja00028a073. [DOI] [Google Scholar]
  4. Bedrood S, Li Y, Isas JM, Hegde BG, Baxa U, Haworth IS, Langen R. Fibril structure of human islet amyloid polypeptide. The Journal of Biological Chemistry. 2012;287:5235–5241. doi: 10.1074/jbc.M111.327817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bram Y, Frydman-Marom A, Yanai I, Gilead S, Shaltiel-Karyo R, Amdursky N, Gazit E. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies. Scientific Reports. 2014;4:4267. doi: 10.1038/srep04267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annual Review of Cell and Developmental Biology. 1999;15:269–290. doi: 10.1146/annurev.cellbio.15.1.269. [DOI] [PubMed] [Google Scholar]
  7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. doi: 10.2337/diabetes.52.1.102. [DOI] [PubMed] [Google Scholar]
  8. Cao P, Tu LH, Abedini A, Levsh O, Akter R, Patsalo V, Schmidt AM, Raleigh DP. Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20. Journal of Molecular Biology. 2012;421:282–295. doi: 10.1016/j.jmb.2011.12.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity : all-atom structure validation for macromolecular crystallography. Acta Crystallographica Section D Biological Crystallography. 2010;66:12–21. doi: 10.1107/S0907444909042073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography. Acta Crystallographica. Section D, Biological Crystallography. 1994;50:760–763. doi: 10.1107/S0907444994003112. [DOI] [PubMed] [Google Scholar]
  11. Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D. Molecular basis for amyloid-beta polymorphism. PNAS. 2011;108:16938–16943. doi: 10.1073/pnas.1112600108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science. 1983;221:709–713. doi: 10.1126/science.6879170. [DOI] [PubMed] [Google Scholar]
  13. Cooper GJ, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, Rothbard JB, Willis AC, Reid KB. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. PNAS. 1988;85:7763–7766. doi: 10.1073/pnas.85.20.7763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cooper S, Khatib F, Treuille A, Barbero J, Lee J, Beenen M, Leaver-Fay A, Baker D, Popović Z, Players F. Predicting protein structures with a multiplayer online game. Nature. 2010;466:756–760. doi: 10.1038/nature09304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Diederichs K, Karplus PA. Better models by discarding data? Acta Crystallographica Section D Biological Crystallography. 2013;69:1215–1222. doi: 10.1107/S0907444913001121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188–1203. doi: 10.1016/j.cell.2012.02.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Eisenberg DS, Wesson M, Yamashita M. Interpretation of protein folding and binding with atomic solvation parameters. Chemica Scripta. 1989;29A:217–221. [Google Scholar]
  18. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallographica. Section D, Biological Crystallography. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
  19. Esapa C, Moffitt JH, Novials A, McNamara CM, Levy JC, Laakso M, Gomis R, Clark A. Islet amyloid polypeptide gene promoter polymorphisms are not associated with type 2 diabetes or with the severity of islet amyloidosis. Biochimica Et Biophysica Acta. 2005;1740:74–78. doi: 10.1016/j.bbadis.2005.02.001. [DOI] [PubMed] [Google Scholar]
  20. Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, Lauris V. Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. PNAS. 1980;77:3519–3523. doi: 10.1073/pnas.77.6.3519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goldsbury C, Goldie K, Pellaud J, Seelig J, Frey P, Müller SA, Kistler J, Cooper GJ, Aebi U. Amyloid fibril formation from full-length and fragments of amylin. Journal of Structural Biology. 2000;130:352–362. doi: 10.1006/jsbi.2000.4268. [DOI] [PubMed] [Google Scholar]
  22. Goldsbury CS, Cooper GJ, Goldie KN, Müller SA, Saafi EL, Gruijters WT, Misur MP, Engel A, Aebi U, Kistler J. Polymorphic fibrillar assembly of human amylin. Journal of Structural Biology. 1997;119:17–27. doi: 10.1006/jsbi.1997.3858. [DOI] [PubMed] [Google Scholar]
  23. Griffiths JM, Ashburn TT, Auger M, Costa PR, Griffin RG, Lansbury PT. Rotational resonance solid-state NMR elucidates a structural model of pancreatic amyloid. Journal of the American Chemical Society. 1995;117:3539–3546. doi: 10.1021/ja00117a023. [DOI] [Google Scholar]
  24. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocrine Reviews. 2008;29:303–316. doi: 10.1210/er.2007-0037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hattne J, Reyes FE, Nannenga BL, Shi D, de la Cruz MJ, Leslie AGW, Gonen T. MicroED data collection and processing. Acta Crystallographica Section a Foundations and Advances. 2015;71:353–360. doi: 10.1107/S2053273315010669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hiddinga HJ, Eberhardt NL. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. The American Journal of Pathology. 1999;154:1077–1088. doi: 10.1016/S0002-9440(10)65360-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, Butler PC. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes. 2007;56:2016–2027. doi: 10.2337/db07-0197. [DOI] [PubMed] [Google Scholar]
  28. Hull RL, Shen ZP, Watts MR, Kodama K, Carr DB, Utzschneider KM, Zraika S, Wang F, Kahn SE. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes. 2005b;54:2235–2244. doi: 10.2337/diabetes.54.7.2235. [DOI] [PubMed] [Google Scholar]
  29. Hull RL, Watts MR, Kodama K, Shen Z, Utzschneider KM, Carr DB, Vidal J, Kahn SE. Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. AJP: Endocrinology and Metabolism. 2005a;289:E703–E709. doi: 10.1152/ajpendo.00471.2004. [DOI] [PubMed] [Google Scholar]
  30. Höppener JW, Ahrén B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. The New England Journal of Medicine. 2000;343:411–419. doi: 10.1056/NEJM200008103430607. [DOI] [PubMed] [Google Scholar]
  31. Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D. Molecular basis for insulin fibril assembly. PNAS. 2009;106:18990–18995. doi: 10.1073/pnas.0910080106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Jack E, Newsome M, Stockley PG, Radford SE, Middleton DA. The organization of aromatic side groups in an amyloid fibril probed by solid-state 2h and 19f NMR spectroscopy. Journal of the American Chemical Society. 2006;128:8098–8099. doi: 10.1021/ja0581898. [DOI] [PubMed] [Google Scholar]
  33. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. PNAS. 1996;93:7283–7288. doi: 10.1073/pnas.93.14.7283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, Aston-Mourney K, Carr DB, Westermark P, Westermark GT, Kahn SE, Hull RL. β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. The American Journal of Pathology. 2011;178:2632–2640. doi: 10.1016/j.ajpath.2011.02.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kabsch W. XDS. Acta Crystallographica. Section D, Biological Crystallography. 2010;66:125–132. doi: 10.1107/S0907444909047337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–1083. doi: 10.1016/S0140-6736(13)62154-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Kajava AV, Aebi U, Steven AC. The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin. Journal of Molecular Biology. 2005;348:247–252. doi: 10.1016/j.jmb.2005.02.029. [DOI] [PubMed] [Google Scholar]
  38. Kapurniotu A. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers. 2001;60:438–459. doi: 10.1002/1097-0282(2001)60:6&#x0003c;438::AID-BIP10182&#x0003e;3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  39. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration. 2007;2:18. doi: 10.1186/1750-1326-2-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology. 1982;157:105–132. doi: 10.1016/0022-2836(82)90515-0. [DOI] [PubMed] [Google Scholar]
  41. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, Pensalfini A, Soriaga AB, Landau M, Teng PK, Cascio D, Glabe C, Eisenberg D. Atomic view of a toxic amyloid small oligomer. Science. 2012;335:1228–1231. doi: 10.1126/science.1213151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces. Journal of Molecular Biology. 1993;234:946–950. doi: 10.1006/jmbi.1993.1648. [DOI] [PubMed] [Google Scholar]
  43. Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. Journal of Molecular Biology. 1971;55:379–400. doi: 10.1016/0022-2836(71)90324-X. [DOI] [PubMed] [Google Scholar]
  44. Lee SC, Hashim Y, Li JK, Ko GT, Critchley JA, Cockram CS, Chan JC. The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels. Clinical Endocrinology. 2001;54:541–546. doi: 10.1046/j.1365-2265.2001.01244.x. [DOI] [PubMed] [Google Scholar]
  45. Lin CY, Gurlo T, Kayed R, Butler AE, Haataja L, Glabe CG, Butler PC. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes. 2007;56:1324–1332. doi: 10.2337/db06-1579. [DOI] [PubMed] [Google Scholar]
  46. Liu C, Sawaya MR, Eisenberg D. β₂-microglobulin forms three-dimensional domain-swapped amyloid fibrils with disulfide linkages. Nature structural & molecular biology. 2011;18:49–55. doi: 10.1038/nsmb.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Liu C, Zhao M, Jiang L, Cheng PN, Park J, Sawaya MR, Pensalfini A, Gou D, Berk AJ, Glabe CG, Nowick J, Eisenberg D. Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. PNAS. 2012;109:20913–20918. doi: 10.1073/pnas.1218792109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Liu S, Hattne J, Reyes FE, Sanchez-Martinez S, Jason de la Cruz M, Shi D, Gonen T. Atomic resolution structure determination by the cryo-EM method MicroED. Protein Science : A Publication of the Protein Society. 2016;00:1–8. doi: 10.1002/pro.2989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) reduction. Journal of Neurochemistry. 1997;69:581–593. doi: 10.1046/j.1471-4159.1997.69020581.x. [DOI] [PubMed] [Google Scholar]
  50. Liu Y, Schubert D. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. Journal of Neurochemistry. 1997;69:2285–2293. doi: 10.1046/j.1471-4159.1997.69062285.x. [DOI] [PubMed] [Google Scholar]
  51. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of Amylin associated with type-2 diabetes mellitus. Nature. 1994;368:756–760. doi: 10.1038/368756a0. [DOI] [PubMed] [Google Scholar]
  52. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. PNAS. 1994;91:12243–12247. doi: 10.1073/pnas.91.25.12243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Luca S, Yau WM, Leapman R, Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry. 2007;46:13505–13522. doi: 10.1021/bi701427q. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Madine J, Jack E, Stockley PG, Radford SE, Serpell LC, Middleton DA. Structural insights into the polymorphism of amyloid-like fibrils formed by region 20-29 of Amylin revealed by solid-state NMR and X-ray fiber diffraction. Journal of the American Chemical Society. 2008;130:14990–15001. doi: 10.1021/ja802483d. [DOI] [PubMed] [Google Scholar]
  55. Magzoub M, Miranker AD. Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2012;26:1228–1238. doi: 10.1096/fj.11-194613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Maloy AL, Longnecker DS, Greenberg ER. The relation of islet amyloid to the clinical type of diabetes. Human Pathology. 1981;12:917–922. doi: 10.1016/S0046-8177(81)80197-9. [DOI] [PubMed] [Google Scholar]
  57. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallographica Section D Biological Crystallography. 2005;61:458–464. doi: 10.1107/S0907444905001617. [DOI] [PubMed] [Google Scholar]
  58. McCoy AJ. Solving structures of protein complexes by molecular replacement with phaser. Acta Crystallographica. Section D, Biological Crystallography. 2007;63:32–41. doi: 10.1107/S0907444906045975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Meier DT, Entrup L, Templin AT, Hogan MF, Mellati M, Zraika S, Hull RL, Kahn SE. The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia. 2016;59:2166–2171. doi: 10.1007/s00125-016-4045-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Meier JJ, Kayed R, Lin C-Y, Gurlo T, Haataja L, Jayasinghe S, Langen R, Glabe CG, Butler PC. Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. AJP: Endocrinology and Metabolism. 2006;291:E1317–E1324. doi: 10.1152/ajpendo.00082.2006. [DOI] [PubMed] [Google Scholar]
  61. Meng F, Abedini A, Plesner A, Verchere CB, Raleigh DP. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry. 2010;49:8127–8133. doi: 10.1021/bi100939a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Mirecka EA, Feuerstein S, Gremer L, Schröder GF, Stoldt M, Willbold D, Hoyer W. β-hairpin of islet amyloid polypeptide bound to an aggregation inhibitor. Scientific Reports. 2016;6:33474. doi: 10.1038/srep33474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Moriarty DF, Raleigh DP. Effects of sequential proline substitutions on amyloid formation by human amylin20-29. Biochemistry. 1999;38:1811–1818. doi: 10.1021/bi981658g. [DOI] [PubMed] [Google Scholar]
  64. Morita S, Sakagashira S, Ueyama M, Shimajiri Y, Furuta M, Sanke T. Progressive deterioration of insulin secretion in japanese type 2 diabetic patients in comparison with those who carry the S20G mutation of the islet amyloid polypeptide gene: A long-term follow-up study. Journal of Diabetes Investigation. 2011;2:287–292. doi: 10.1111/j.2040-1124.2011.00102.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods. 1983;65:55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  66. Mukherjee A, Morales-Scheihing D, Butler PC, Soto C. Type 2 diabetes as a protein misfolding disease. Trends in Molecular Medicine. 2015;21:439–449. doi: 10.1016/j.molmed.2015.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Mulder H, Ling C. Mitochondrial dysfunction in pancreatic beta-cells in type 2 diabetes. Molecular and Cellular Endocrinology. 2009;297:34–40. doi: 10.1016/j.mce.2008.05.015. [DOI] [PubMed] [Google Scholar]
  68. Nannenga BL, Shi D, Hattne J, Reyes FE, Gonen T. Structure of catalase determined by MicroED. eLife. 2014a;3:e03600. doi: 10.7554/eLife.03600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Nannenga BL, Shi D, Leslie AG, Gonen T. High-resolution structure determination by continuous-rotation data collection in MicroED. Nature Methods. 2014b;11:1–5. doi: 10.1038/nmeth.3043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 2005;435:773–778. doi: 10.1038/nature03680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Nielsen JT, Bjerring M, Jeppesen MD, Pedersen RO, Pedersen JM, Hein KL, Vosegaard T, Skrydstrup T, Otzen DE, Nielsen NC. Unique identification of supramolecular structures in amyloid fibrils by solid-state NMR spectroscopy. Angewandte Chemie International Edition. 2009;48:2118–2121. doi: 10.1002/anie.200804198. [DOI] [PubMed] [Google Scholar]
  72. Nishi M, Chan SJ, Nagamatsu S, Bell GI, Steiner DF. Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone. PNAS. 1989;86:5738–5742. doi: 10.1073/pnas.86.15.5738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL. Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. The American Journal of Pathology. 1995;147:609–616. [PMC free article] [PubMed] [Google Scholar]
  74. Opie EL. The relation oe diabetes mellitus to lesions of the pancreas. hyaline degeneration of the islands OE langerhans. Journal of Experimental Medicine. 1901;5:527–541. doi: 10.1084/jem.5.5.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Oskarsson ME, Singh K, Wang J, Vlodavsky I, Li JP, Westermark GT. Heparan sulfate proteoglycans are important for islet amyloid formation and islet amyloid Polypeptide-induced apoptosis. The Journal of Biological Chemistry. 2015;290:15121–15132. doi: 10.1074/jbc.M114.631697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Paulsson JF, Schultz SW, Köhler M, Leibiger I, Berggren P-O, Westermark GT. Real-time monitoring of apoptosis by caspase-3-like protease induced FRET reduction triggered by amyloid aggregation. Experimental Diabetes Research. 2008;2008:1–12. doi: 10.1155/2008/865850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Pilkington EH, Gurzov EN, Kakinen A, Litwak SA, Stanley WJ, Davis TP, Ke PC. Pancreatic β-Cell membrane fluidity and toxicity induced by human islet amyloid polypeptide species. Scientific Reports. 2016;6:21274. doi: 10.1038/srep21274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Richards FM. Areas, volumes, packing, and protein structure. Annual Review of Biophysics and Bioengineering. 1977;6:151–176. doi: 10.1146/annurev.bb.06.060177.001055. [DOI] [PubMed] [Google Scholar]
  79. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes. 2007;56:65–71. doi: 10.2337/db06-0734. [DOI] [PubMed] [Google Scholar]
  80. Roberts AN, Leighton B, Todd JA, Cockburn D, Schofield PN, Sutton R, Holt S, Boyd Y, Day AJ, Foot EA. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. PNAS. 1989;86:9662–9666. doi: 10.1073/pnas.86.24.9662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS. Structure of the toxic core of α-synuclein from invisible crystals. Nature. 2015;525:486–490. doi: 10.1038/nature15368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K, Eberhardt NL. S20G mutant Amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type Amylin. The American Journal of Pathology. 2000;157:2101–2109. doi: 10.1016/S0002-9440(10)64848-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes. 1996;45:1279–1281. doi: 10.2337/diab.45.9.1279. [DOI] [PubMed] [Google Scholar]
  84. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen AØ, Riekel C, Eisenberg D. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447:453–457. doi: 10.1038/nature05695. [DOI] [PubMed] [Google Scholar]
  85. Schlamadinger DE, Miranker AD. Fiber-dependent and -independent toxicity of islet amyloid polypeptide. Biophysical Journal. 2014;107:2559–2566. doi: 10.1016/j.bpj.2014.09.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. PNAS. 1995;92:1989–1993. doi: 10.1073/pnas.92.6.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces aβ plaques in Alzheimer's disease. Nature. 2016;537:50–56. doi: 10.1038/nature19323. [DOI] [PubMed] [Google Scholar]
  88. Shi D, Nannenga BL, de la Cruz MJ, Liu J, Sawtelle S, Calero G, Reyes FE, Hattne J, Gonen T. The collection of MicroED data for macromolecular crystallography. Nature Protocols. 2016;11:895–904. doi: 10.1038/nprot.2016.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Shi D, Nannenga BL, Iadanza MG, Gonen T. Three-dimensional electron crystallography of protein microcrystals. eLife. 2013;2:e01345. doi: 10.7554/eLife.01345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Sievers SA, Karanicolas J, Chang HW, Zhao A, Jiang L, Zirafi O, Stevens JT, Münch J, Baker D, Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature. 2011;475:96–100. doi: 10.1038/nature10154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Soriaga AB, Sangwan S, Macdonald R, Sawaya MR, Eisenberg D. Crystal structures of IAPP amyloidogenic segments reveal a novel packing motif of out-of-register beta sheets. The Journal of Physical Chemistry B. 2016;120:5810–5816. doi: 10.1021/acs.jpcb.5b09981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of Molecular Biology. 1997;273:729–739. doi: 10.1006/jmbi.1997.1348. [DOI] [PubMed] [Google Scholar]
  93. Tenidis K, Waldner M, Bernhagen J, Fischle W, Bergmann M, Weber M, Merkle ML, Voelter W, Brunner H, Kapurniotu A. Identification of a Penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. Journal of Molecular Biology. 2000;295:1055–1071. doi: 10.1006/jmbi.1999.3422. [DOI] [PubMed] [Google Scholar]
  94. Tomasello MF, Sinopoli A, Attanasio F, Giuffrida ML, Campagna T, Milardi D, Pappalardo G. Molecular and cytotoxic properties of hIAPP17-29 and rIAPP17-29 fragments: a comparative study with the respective full-length parent polypeptides. European Journal of Medicinal Chemistry. 2014;81:442–455. doi: 10.1016/j.ejmech.2014.05.038. [DOI] [PubMed] [Google Scholar]
  95. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. PNAS. 1996;93:3492–3496. doi: 10.1073/pnas.93.8.3492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Weirich F, Gremer L, Mirecka EA, Schiefer S, Hoyer W, Heise H. Structural characterization of fibrils from recombinant human islet amyloid polypeptide by Solid-State NMR: The central FGAILS segment is part of the β-Sheet core. PLoS One. 2016;11:e0161243. doi: 10.1371/journal.pone.0161243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Molecular Medicine. 2000;6:998–1007. [PMC free article] [PubMed] [Google Scholar]
  98. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews. 2011;91:795–826. doi: 10.1152/physrev.00042.2009. [DOI] [PubMed] [Google Scholar]
  99. Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. PNAS. 1990;87:5036–5040. doi: 10.1073/pnas.87.13.5036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. PNAS. 1987;84:3881–3885. doi: 10.1073/pnas.84.11.3881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Wiltzius JJ, Landau M, Nelson R, Sawaya MR, Apostol MI, Goldschmidt L, Soriaga AB, Cascio D, Rajashankar K, Eisenberg D. Molecular mechanisms for protein-encoded inheritance. Nature Structural & Molecular Biology. 2009a;16:973–978. doi: 10.1038/nsmb.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Wiltzius JJ, Sievers SA, Sawaya MR, Cascio D, Popov D, Riekel C, Eisenberg D. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin) Protein Science : A Publication of the Protein Society. 2008;17:1467–1474. doi: 10.1110/ps.036509.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Wiltzius JJ, Sievers SA, Sawaya MR, Eisenberg D. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Science : A Publication of the Protein Society. 2009b;18:1521–1530. doi: 10.1002/pro.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Wineman-Fisher V, Atsmon-Raz Y, Miller Y. Orientations of residues along the β-arch of self-assembled Amylin fibril-like structures lead to polymorphism. Biomacromolecules. 2015;16:156–165. doi: 10.1021/bm501326y. [DOI] [PubMed] [Google Scholar]
  105. Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, Glabe C. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. The Journal of Biological Chemistry. 2010;285:6071–6079. doi: 10.1074/jbc.M109.069542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu LH, Raleigh DP, Radford SE, Ashcroft AE. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nature Chemistry. 2015;7:73–81. doi: 10.1038/nchem.2129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Yu L, Lee SJ, Yee VC. Crystal structures of polymorphic prion protein β1 peptides reveal variable steric zipper conformations. Biochemistry. 2015;54:3640–3648. doi: 10.1021/acs.biochem.5b00425. [DOI] [PubMed] [Google Scholar]
  108. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Kahn SE. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia. 2010;53:1046–1056. doi: 10.1007/s00125-010-1671-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
eLife. 2017 Jan 3;6:e19273. doi: 10.7554/eLife.19273.025

Decision letter

Editor: Nir Ben-Tal1

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "Atomic Structures of Fibrillar Segments of Islet Amyloid Polypeptide Suggest Tightly Mated β-Sheets Drive Cytotoxicity" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor, Nir Ben-Tal, and Michael Marletta as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript addresses the important and controversial topic of human islet amyloid polypeptide (hIAPP) toxicity via a mostly structural study. The work is technically excellent, the use of Cryo electron microscopy-based MicroED is highly suitable for the scientific quest and the addition of the biological data is very important. The main conclusion is that the fibrillar form of hIAPP segment 19-29S20G is toxic, but its oligomeric form is not. In addition, in- or out-of registration/hydrophobicity of the four IAPP segments of interest in fibrillation is insufficient to account for the observed differential toxicity. This study concludes that 19-29S20G could be used as a model system for examining hIAPP aggregation and toxicity. The work is elegant and it provides important insights on the cytotoxicity of the polypeptide that is associated with Type II diabetes. The conclusions are consistent with the experimental results and the Discussion is very good. On the other hand, it is somewhat surprising that this manuscript heavily emphasizes on cytotoxicity – a not so very original point of this study, while the more novel structural observations are only mentioned in passing. If revised, it could be suitable for eLife.

Essential revisions:

1) The authors make it appear as if fibrils (and not oligomers or other intermediates) are generally considered as the major cytotoxic species of IAPP. However, there is very abundant literature evidence that oligomers and not fibrils are the major cytotoxic species, and the current study also does not explicitly analyze oligomer samples. The current description might be motivated by bad experiences with journal editors or referees who frequently dismiss all work on fibrils as being irrelevant and notoriously believe the pathology of any protein misfolding disease to solely depend on oligomers. This concept, while being too simple minded, is wide spread and causes numerous problems when attempting to publish solid scientific work. Yet, I also think that it is problematic to neglect the considerable body of published evidence in favor of the toxicity of IAPP oligomers, although there are also studies reporting the in vitro toxicity of fibrils, at least in certain set ups. Therefore, the following sentences should be changed:

"Researchers have accumulated substantial evidence that supports a causative link between hIAPP aggregation and islet cell death leading to T2D" and "Consistent with this causation, mouse IAPP does not aggregate and mice do not get T2D. However, mice can be induced to develop islet amyloid and T2D when they are engineered to express human IAPP and fed a high fat diet (Verchere et al., 2996; Westermark et al., 2000). Perhaps the strongest support for a causative link is the mutation in hIAPP, hIAPP-S20G; segments containing this mutation aggregate more quickly and lead to early onset T2D in families who carry this lesion" suggest that IAPP toxicity causes T2D (type 2 diabetes). We think that no medical scientist would agree to this notion. Instead, IAPP aggregation is rather thought to constitute a secondary complication of T2D that actually develops for other reasons. The above sentences should be removed or changed such that they no longer imply that IAPP aggregation causes T2D.

"The causative link between hIAPP amyloid fibril formation and islet cell death is widely accepted, but researchers have debated whether soluble, pre-fibrillar oligomers or amyloid fibrils are the primary cytotoxic species that drive islet cell death" and "researchers suggested that amyloid fibrils are the primary cytotoxic species because hIAPP is only cytotoxic in its fibrillar form", "if hIAPP fibrils are the primary cytotoxic species, then determining the atomic structure of the spine of hIAPP fibrils is a logical approach for advancing our understanding of disease-relevant targets", and "we focused on studying fibrillar structures of hIAPP as the more relevant to cytotoxicity". These statements turn the currently dominating belief in the field rather upside down. Pre-fibrillar oligomers and other intermediates (and not fibrils) are nowadays considered to be the major toxic species of IAPP, although this evidence is largely based on in vitro studies and the in vivo pathogenic agents remain to be established. This view can be found, for example, in the very influential review from G. Westermark (Physiological Reviews 2011 Vol. 91 no. 3, 795-826), one of the coauthors of the current study, where it says that "the mature amyloid fibril is presumed to be relatively inert and to have no significant cell toxicity. Rather, smaller oligomeric intermediates formed during fibrillogenesis are thought to be cytotoxic". The above statements should be amended.

The following statement was used to support that residues 15-29 are important for toxicity: "previous work by our laboratory has shown that Phe15 is required for stabilizing an on-pathway α-helical dimer and that mutating this residue can delay aggregation". However, it solely describes aggregation and not toxicity. Please amend.

"The cytotoxicity of hIAPP resides mainly in its fibrillar form" and "here, we offer support for mature amyloid fibrils as a major type of aggregate responsible for islet cell death by showing that fibrillar hIAPP is significantly more cytotoxic to cultured pancreatic β-cells than pre-fibrillar forms". These statements are questionable as the presently reported cytotoxicity measurements did not explicitly test oligomer samples.

The origin of divergence in the literature regarding the identity of the toxic entity perhaps has to do with the rapid fibrillation rate of hIAPP compared with, say, amyloid-β, where isolation of hIAPP monomers, oligomers, protofibrils and mature fibrils is nontrivial, as the authors also acknowledged. Since toxicity is the biological endpoint of a chemical (e.g., ROS), physical (amyloids, oligomers and their associated hydrophobicity/membrane partitioning, assembly kinetics, assembly with intra- and extracellular proteins) or biological (the triangle between insulin, amylin and glucose etc.) trigger, it seems to make more sense that it is the combined contributions of these aspects, different for hIAPP fibrils and oligomers in each aspect, induce the toxicity of hIAPP.

2) If indeed the fibrillar form of the polypeptide is the toxic element, could antibodies raised against this form be a treatment for Type II diabetes? Unlike the case of amyloid-β vaccination, the risk of meningoencephalitis is not a concern.

3) What could be the cause that out of registration amyloid proteins behave so differently, as acknowledged by the authors in the Discussion (fifth paragraph)? Does it suggest that the structural properties of protein monomers/amyloids may not be the only source to explain toxicity?

4) It might be beneficial to compare the overall hydrophobicity and charge of the four segments to decipher their differential toxicity as reported in this paper.

5) All "cytotoxicity" data in Figure 1B are solely based on the MTT assay, which is known to sometimes produce false positive results. See, for example J Biol Chem. 2014 289: 35781-94. These measurements need to be confirmed with another assay.

6) Figure 1A: the "dot blot" with hIAPP is not of suitable quality for evaluation, as it only shows a black image. No conclusion is possible based on these data.

7) Figure 6 is not able to show a templating of toxicity by a fragment onto full-length IAPP. The 10% 19-29 S20G fibril seeds produced the same toxicity as full-length hIAPP without seeds, while 15-25 WT seeds reduced toxicity. The most straightforward interpretation of these findings is probably that 19-29 S20G fibril seeds did not affect the formation of toxic species from hIAPP, while 15-25 WT seeds interact with hIAPP to reduce its toxicity. We do not see how this experiment justifies the conclusion that there is seeding of toxic activity.

8) What could/should be emphasized much more clearly (specifically in the Discussion) are the following issues:

A) The current cross-β sheets are concave or convex when you look down the spine axis. This curvature is a major difference to Madine et al., 2008, and probably also most previous steric zippers consisting of short chains. What does this curvature mean or what enforces it?

B) Associated with this observation, Figure 3 shows different backbone distances at the outer ends of the zipper and in the center. This variation of the packing distance could be an important new observation.

C) Most steric zippers have the strands oriented perpendicular to the sheet long axis. This is not the case in Figure 4. Why?

D) How does the current packing of the zippers relate to the ones seen in earlier zipper described for IAPP (Nature Structural & Molecular Biology 16, 973 – 978, 2009)? Do the small zippers show the same interactions as the large ones? If not, what does it mean for the specificity of the side-chain interactions in the fibril?

eLife. 2017 Jan 3;6:e19273. doi: 10.7554/eLife.19273.026

Author response


Essential revisions:

1) The authors make it appear as if fibrils (and not oligomers or other intermediates) are generally considered as the major cytotoxic species of IAPP. However, there is very abundant literature evidence that oligomers and not fibrils are the major cytotoxic species, and the current study also does not explicitly analyze oligomer samples. The current description might be motivated by bad experiences with journal editors or referees who frequently dismiss all work on fibrils as being irrelevant and notoriously believe the pathology of any protein misfolding disease to solely depend on oligomers. This concept, while being too simple minded, is wide spread and causes numerous problems when attempting to publish solid scientific work. Yet, I also think that it is problematic to neglect the considerable body of published evidence in favor of the toxicity of IAPP oligomers, although there are also studies reporting the in vitro toxicity of fibrils, at least in certain set ups. Therefore, the following sentences should be changed:

We have amended the manuscript to note that several current studies of hIAPP have implicated oligomers as the toxic agents (Introduction, third paragraph). Thank you for suggesting this point.

"Researchers have accumulated substantial evidence that supports a causative link between hIAPP aggregation and islet cell death leading to T2D" and "Consistent with this causation, mouse IAPP does not aggregate and mice do not get T2D. However, mice can be induced to develop islet amyloid and T2D when they are engineered to express human IAPP and fed a high fat diet (Verchere et al., 2996; Westermark et al., 2000). Perhaps the strongest support for a causative link is the mutation in hIAPP, hIAPP-S20G; segments containing this mutation aggregate more quickly and lead to early onset T2D in families who carry this lesion" suggest that IAPP toxicity causes T2D (type 2 diabetes). We think that no medical scientist would agree to this notion. Instead, IAPP aggregation is rather thought to constitute a secondary complication of T2D that actually develops for other reasons. The above sentences should be removed or changed such that they no longer imply that IAPP aggregation causes T2D.

We have amended the manuscript to remove any assertion of causation. We do, however, point out the evidence showing a correlation of hIAPP aggregation to pancreatic β-cell death (Introduction, second paragraph).

"The causative link between hIAPP amyloid fibril formation and islet cell death is widely accepted, but researchers have debated whether soluble, pre-fibrillar oligomers or amyloid fibrils are the primary cytotoxic species that drive islet cell death".

In the amended manuscript we have removed the term “causative”.

And "researchers suggested that amyloid fibrils are the primary cytotoxic species because hIAPP is only cytotoxic in its fibrillar form", "if hIAPP fibrils are the primary cytotoxic species, then determining the atomic structure of the spine of hIAPP fibrils is a logical approach for advancing our understanding of disease-relevant targets", and "we focused on studying fibrillar structures of hIAPP as the more relevant to cytotoxicity".

These sentences have been amended in the revised manuscript (Introduction, third paragraph and subsection “hIAPP preparations that contain fibrils are cytotoxic to cultured rat pancreatic β-cells”, last paragraph.

These statements turn the currently dominating belief in the field rather upside down. Pre-fibrillar oligomers and other intermediates (and not fibrils) are nowadays considered to be the major toxic species of IAPP, although this evidence is largely based on in vitro studies and the in vivo pathogenic agents remain to be established. This view can be found, for example, in the very influential review from G. Westermark (Physiological Reviews 2011 Vol. 91 no. 3, 795-826), one of the coauthors of the current study, where it says that "the mature amyloid fibril is presumed to be relatively inert and to have no significant cell toxicity. Rather, smaller oligomeric intermediates formed during fibrillogenesis are thought to be cytotoxic". The above statements should be amended.

Thank you for noting the important difference between in vitro and in vivo studies, which we now mention in the third paragraph of the Introduction. We do not, however, get into the mechanism of hIAPP action on cells; we restrict ourselves to reporting our observations of toxicity without proposing a mechanism. Our private hypothesis is that the mechanism may involve both mature fibrils and smaller species, perhaps short fibrils. That is, amyloid fibril deposition leads to distortion of the histological structure of the affected organ. Islet hormone release is dependent on the islet architecture and regulated insulin release requires cell-cell interaction via connexin-36. When hIAPP amyloid deposits extracellularly it results in separation of the β cells and loss of synchronized hormone release. Islet amyloid occurs perivascular and sometimes prominent deposits occur, possibly influencing diffusion of oxygen and nutrients. Whereas mature amyloid fibrils may exert no direct β cell cytotoxicity, amyloid fibrils somehow affect islet function, and the results of our paper may contribute to the ultimate understanding of the mechanism.

Although we do not propose a mechanism, we report one experiment that may bear on it. With our FRET-based amyloid toxicity assay, we showed that the amyloid fibril formation-process induced toxicity (Figure 5D, E). An earlier study using the same assay revealed that the fibril formation-process is cytotoxic when it took place in contact with the cell surface, and the toxicity ceased when fibril formation was halted (Oskarsson, 2015, JBC). Thus, our data support that hIAPP-amyloid fibril formation induces cell toxicity, but amyloid fibrils neutralize the toxicity.

The following statement was used to support that residues 15-29 are important for toxicity: "previous work by our laboratory has shown that Phe15 is required for stabilizing an on-pathway α-helical dimer and that mutating this residue can delay aggregation". However, it solely describes aggregation and not toxicity. Please amend.

We amended the wording to make our intended statement clearer. It now reads: “Third, previous work by our laboratory has shown that Phe15 may be part of the amyloid spine because it is required for stabilizing an on-pathway α-helical dimer and mutating this residue can delay fibril formation (Wiltzius et al., 2009).”

"The cytotoxicity of hIAPP resides mainly in its fibrillar form" and "here, we offer support for mature amyloid fibrils as a major type of aggregate responsible for islet cell death by showing that fibrillar hIAPP is significantly more cytotoxic to cultured pancreatic β-cells than pre-fibrillar forms". These statements are questionable as the presently reported cytotoxicity measurements did not explicitly test oligomer samples.

In order to address this revision and essential revisions #5 and #6, we repeated the cytotoxicity studies shown in Figure 1 and Figure 1—figure supplement 1 with some modifications. The most important modification was that we used half the concentration of IAPP that we used in our original studies. This modification allowed us to test the cytotoxicity of oligomer and fibril preparations.

Using the LOC antibody, we detect fibrillar oligomers in the “hIAPP 0 h” preparation. Although the LOC antibody was raised against hIAPP fibrils, previous studies show that it binds to fibrillar oligomers of amyloid-β (Wu, 2010, JBC). Fibrillar oligomers are structurally distinct from pre-fibrillar oligomers, which are recognized by the A11 antibody.

Using two metrics of cytotoxicity, we find that hIAPP preparations that contain these fibrillar oligomers are significantly less cytotoxic than hIAPP preparations that contain fibrils and no detectable oligomers. The full description of these results starts in the subsection “hIAPP preparations that contain fibrils are cytotoxic to cultured rat pancreatic β-cells”.

The above statements were amended to reflect our updated cytotoxicity studies. They now read: “We observe that hIAPP preparations that contain fibrils are significantly more cytotoxic to rat pancreatic β-cells than hIAPP preparations that contain oligomers but no detectable fibrils (Figure 1B,C)”; and “In closer agreement with earlier studies, we find that hIAPP preparations that contain fibrils are cytotoxic to rat pancreatic β-cells, thus motivating us to determine the structure of the spine of hIAPP fibrils.”

The origin of divergence in the literature regarding the identity of the toxic entity perhaps has to do with the rapid fibrillation rate of hIAPP compared with, say, amyloid-β, where isolation of hIAPP monomers, oligomers, protofibrils and mature fibrils is nontrivial, as the authors also acknowledged. Since toxicity is the biological endpoint of a chemical (e.g., ROS), physical (amyloids, oligomers and their associated hydrophobicity/membrane partitioning, assembly kinetics, assembly with intra- and extracellular proteins) or biological (the triangle between insulin, amylin and glucose etc.) trigger, it seems to make more sense that it is the combined contributions of these aspects, different for hIAPP fibrils and oligomers in each aspect, induce the toxicity of hIAPP.

Good point. But we do not have evidence for mechanism, so we prefer not to discuss this thoroughly. However, we acknowledge the potential disconnect between toxic aggregates identified in vitro and toxic aggregates present in vivo in the third paragraph of the Introduction and we briefly mention the possibility of multi-variable toxicity in the sixth paragraph of the Discussion.

2) If indeed the fibrillar form of the polypeptide is the toxic element, could antibodies raised against this form be a treatment for Type II diabetes? Unlike the case of amyloid-β vaccination, the risk of meningoencephalitis is not a concern.

Presumably, yes. We mention this in the Discussion of this revised submission (last paragraph).

3) What could be the cause that out of registration amyloid proteins behave so differently, as acknowledged by the authors in the Discussion (fifth paragraph)? Does it suggest that the structural properties of protein monomers/amyloids may not be the only source to explain toxicity?

One potential cause for the different cytotoxic effects of the 2 out-of-register protein segments is whether or not the out-of-register sheets are mated. Mildly cytotoxic protein segment KDWSFY from β-2 microglobulin has sheets mated by a dry interface, but non-toxic hIAPP 15-25 WT is composed of single sheets. The dry interface of the KDWSFY crystal structure results in higher solvation energy per strand compared to the 15-25 WT crystal structure (122 cal/mol/strand vs. 19 cal/mol/strand). Given that cytotoxic structures like 19-29 S20G have high solvation energies per strand (279 cal/mol/strand; Supplementary file 1), this difference may explain the disparate cytotoxic effects of the two out-of-register structures. However, we need more studies of out-of-register protein structures and their cognate cytotoxicity effects to definitively make this conclusion.

We added this observation to the Discussion of this revised submission (sixth paragraph).

4) It might be beneficial to compare the overall hydrophobicity and charge of the four segments to decipher their differential toxicity as reported in this paper.

We thank the reviewers for making this suggestion. To investigate this and to compare the structures of shorter hIAPP protein segments previously determined, we added Supplementary file 1, which lists many structural and biophysical features of the 15 protein segment crystal structures from hIAPP, including the structures described in this study.

Spine segments 19-29 S20G and 15-25 WT possess similar charges (0 and 0.1 at pH 7, respectively) and only slightly different hydrophobicity values (0.25 and 0.29, respectively) compared to other hIAPP protein segments for which we have crystal structures. Furthermore, the overall charge and hydrophobicity values for cytotoxic full-length hIAPP, (2.1 at pH 7 and – 0.097) are not particularly similar to any of the charges or hydrophobicity values for the protein segments described here. It is difficult to associate 1 biophysical characteristic with cytotoxicity as we only have cytotoxicity data for the 4 protein segments described in this study. Nonetheless, since we observe that the hydrophobicity values for the protein segments described here are close to the average hydrophobicity value for all hIAPP protein segments ever characterized (average = 0.11), we presume overall hydrophobicity and charge of the segments do not fully explain their differential toxicity. It seems more likely that their differential cytotoxicity is better explained by their divergent structures.

5) All "cytotoxicity" data in Figure 1B are solely based on the MTT assay, which is known to sometimes produce false positive results. See, for example J Biol Chem. 2014 289: 35781-94. These measurements need to be confirmed with another assay.

We acknowledge the potential issues of the MTT assay. Of note, in the JBC paper cited by the reviewers, the researchers discovered that only fragmented fibrils, not unfragmented fibrils like those used in our studies, produced false positive results in the MTT assay. Additionally, as the reviewers point out in essential revision #1, our studies described in the original Figure 1 and Figure 1—figure supplement 1 did not explicitly test oligomer samples. Thus, we repeated the cytotoxicity studies with some modifications in order to address these 2 essential revisions and essential revision #6.

By halving the concentration of IAPP that we used in our original studies, we were able to generate oligomer and fibril preparations of hIAPP. In the “hIAPP 0 h” preparation, we detect only fibrillar oligomers and in the “hIAPP 24 h” preparation, we detect only amyloid fibrils.

We tested the cytotoxicity of the samples using the MTT assay and a luminescence-based caspase-3/7 detection assay in parallel. Active caspase-3 and caspase-7 proteases are markers of apoptosis (Budihardjo, 1999, Annu Rev Cell Dev Biol). Both assays show that “hIAPP 24 h,” which contains fibrils and no detectable oligomers, is significantly more cytotoxic than “hIAPP 0 h,” which contains only oligomers. Furthermore, we find that the insoluble fraction of the cytotoxic “hIAPP 24 h” sample is more cytotoxic than the soluble fraction of the sample, providing more evidence for cytotoxicity of fibrils in our studies. We added the results of these studies to Figure 1 and Figure 1—figure supplement 1 in the revised manuscript. A full description of this study is in the subsection “hIAPP preparations that contain fibrils are cytotoxic to cultured rat pancreatic β-cells”.

6) Figure 1A: the "dot blot" with hIAPP is not of suitable quality for evaluation, as it only shows a black image. No conclusion is possible based on these data.

As stated in our response to essential revisions #1 and #5, we repeated the cytotoxicity studies described in the original Figure 1 and Figure 1—figure supplement 1 using a modified setup in order to address the reviewers’ comments on the MTT assay and the absence of oligomers.

Additionally, we performed dot blot assays of the samples used in the cytotoxicity studies with 25 different conformational antibodies known to recognize soluble oligomers. Only one of these antibodies, LOC, gave a robust and consistent result across biological triplicates. We replaced the original dot blot results with the LOC dot blot results in Figure 1 and Figure 1—figure supplement 1. Professor Charles Glabe and Dr. Stephan Philipp from UC Irvine tested our samples with the 25 different conformational antibodies and thus are now co-authors of the manuscript.

7) Figure 6 is not able to show a templating of toxicity by a fragment onto full-length IAPP. The 10% 19-29 S20G fibril seeds produced the same toxicity as full-length hIAPP without seeds, while 15-25 WT seeds reduced toxicity. The most straightforward interpretation of these findings is probably that 19-29 S20G fibril seeds did not affect the formation of toxic species from hIAPP, while 15-25 WT seeds interact with hIAPP to reduce its toxicity. We do not see how this experiment justifies the conclusion that there is seeding of toxic activity.

We agree with the reviewers’ interpretation of the result with hIAPP seeded with toxic 19-29 S20G fibrils. This result does not appear to show a templating of toxicity by a fragment onto full- length hIAPP. However, the result with hIAPP seeded with non-toxic 15-25 WT fibrils may be explained by (1) our interpretation of templating growth of fibrils of relatively low toxicity or (2) by the reviewers’ interpretation of seed interacting with hIAPP to reduce its toxicity. Both interpretations seem reasonable considering that 15-25 WT fibrils template full-length hIAPP fibril formation (Figure 1G in the revised manuscript). We include both interpretations in the revised manuscript. See subsection “Fibril seeds of 15-25 WT reduce the cytotoxicity of full-length hIAPP”, third paragraph.

8) What could/should be emphasized much more clearly (specifically in the Discussion) are the following issues:

A) The current cross-β sheets are concave or convex when you look down the spine axis. This curvature is a major difference to Madine et al., 2008, and probably also most previous steric zippers consisting of short chains. What does this curvature mean or what enforces it?

This subject is addressed more fully in the amended manuscript. The β-sheets in the crystal structures presented here are curved compared to shorter hIAPP protein segments previously determined. To quantify β-sheet deviation from planarity across all protein segment crystal structures, we calculated their standard deviation of atoms from a best-fit plane (Supplementary file 1). Many of the previous steric-zippers are very flat, but some including the 15-25 WT and 19-29 S20G crystal structures are in the top half of deviation magnitude (Figure 3—figure supplement 2; Figure 4—figure supplement 2). Some of the sheets have sharp kinks rather than gradual curves. 19-29 S20G has both. The meaning of the deviations from planarity is not yet clear. These values are included in the newly added Supplementary file 1 and discussed in the Results section.

Our private hypothesis is that kinking and curvature are two mechanisms by which β-sheets may increase the interactions with neighboring sheets. In other words, kinks and curvature impart plasticity to the otherwise strictly planar β-sheet so it may conform to the shape of an adjacent surface to produce tighter dry interfaces (as in the case of 19-29 S20G) or optimize crystal contacts (as in the case of 15-25 WT). Indeed, our modeling studies showed without the kink introduced by the S20G mutation, the 19-29 segment cannot form as tight of a dry interface (see last paragraph in the subsection “Segment 19-29 S20G forms pairs of β-sheets tightly mated by a dry interface”).

We speculate that kinking and curvature are likely to be observed more frequently with increasingly longer segments, since longer segments are likely to have greater variation in side chain lengths and kinks and curves provide additional degrees of freedom for sheets of varying thickness to mate more tightly.

Moreover, we think that kinked sheets are likely to be more common for in-register sheets than out-of-register sheets. We speculate that if the 15-25 WT segment could kink in addition to curving, the new shape would afford another chance that it may conform tightly with neighboring sheets. However, there is likely to be a high energy barrier to introducing a kink in the sheet formed by the 15-25 WT segment because the sheet lacks alignment of glycine residues, which assists with kink formation. Recall that kink formation requires a crease to propagate through the entire length of the sheet. Because the 15-25 WT structure is out of register, Gly24 residues do not align in a continuous line.

B) Associated with this observation, Figure 3 shows different backbone distances at the outer ends of the zipper and in the center. This variation of the packing distance could be an important new observation.

Thank you for this suggestion. To investigate this question, we measured the standard deviation in sheet-to-sheet distance for all hIAPP protein segment structures determined to date. The variation of packing distance appears to accommodate the variation in side-chain sizes protruding from the sheet. This observation is noted in the revised text and it is also included in the newly added Supplementary file 1.

C) Most steric zippers have the strands oriented perpendicular to the sheet long axis. This is not the case in Figure 4. Why?

Indeed, most steric-zippers are formed of β-strands stacked perpendicular to the sheet long axis. We describe such zippers as “in-register.” A few years ago, our group discovered steric-zipper structures that are formed of β-strands that stack at an angle to the sheet long axis. We describe these zippers as “out-of-register.” Deviation of strands from the fibril perpendicular is a natural consequence of the registration shift implied by out-of-register structures. The 15-25 WT crystal structure presented in Figure 4 is an example of the out-of-register-steric-zippers.

To date, only 4 out-of-register steric-zippers have been identified and the significance of the out- of-register stacking of β-strands is not yet well established. It is possible that the out-of-register stacking could infer tendencies for the sheet to roll into a cylinder, like cylindrin does (Laganowsky, 2012, Science). The 4 out-of-register steric-zippers are formed of protein segments derived from β-2 microglobulin (Liu, 2012, PNAS), prion protein (Yu, 2015, Biochemistry), and IAPP (Soriaga, 2015, J Phys Chem Bio) suggesting out-of-register stacking is a shared feature of amyloid proteins.

We expanded our description of out-of-register protein structures in the Results and Discussion sections.

D) How does the current packing of the zippers relate to the ones seen in earlier zipper described for IAPP (Nature Structural & Molecular Biology 16, 973 – 978, 2009)? Do the small zippers show the same interactions as the large ones? If not, what does it mean for the specificity of the side-chain interactions in the fibril?

Crystal structures of shorter hIAPP protein segments exhibit an array of sheet and side-chain interactions, which we term polymorphism. Even shorter protein segments that fully overlap with the 11-residue spine segments described in this work exhibit significant polymorphism. We list the steric-zipper classes and other structural features of each protein segment in the newly added Figure 7 and Supplementary file 1 and we examine the polymorphism across the structures starting in the fourth paragraph of the Discussion.

Furthermore, full-length hIAPP fibril models derived from solid-state NMR studies (Luca, 2007, Biochemistry) also suggest variable side-chain interactions in fibrils. Taken together with the 15 crystal structures of hIAPP protein segments, we surmise that there is some flexibility of side- chain interactions in the fibril.

Nonetheless, the extensive size of the 19-29 S20G dry interface implies it is particularly stable. In comparison, the zippers in our earlier publications have fewer residues and hence, smaller interfaces.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Supplementary file 1. Summary of structural features and biophysical properties of all hIAPP protein segment structures determined to date.

    DOI: http://dx.doi.org/10.7554/eLife.19273.024

    elife-19273-supp1.xls (41.5KB, xls)
    DOI: 10.7554/eLife.19273.024

    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES